



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



European Network of Centres for
Pharmacoepidemiology and
Pharmacovigilance

EMA/95098/2010 Rev.7

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 7)

References

All hyperlinks in the document were last accessed on-line in June 2018

References – Chapter 1

Ali A, Hartzema A. (2018). Post-Authorization Safety Studies of Medicinal Products. The PASS Book (1st ed.). Academic Press.

Altman, D. (2015). Practical Statistics for Medical Research. Chapman & Hall.

Andrews AB, Moore N. (2014). Mann's Pharmacovigilance (3rd ed.). Wiley Blackwell.

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF>

Elseviers M, Wettermark B, Almarsdóttir AB, et al. (2016). Drug Utilization Research: Methods and Applications. Wiley Blackwell.

Guideline of good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=W00b01ac058058f32c

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

Send a question via our website www.ema.europa.eu/contact

An agency of the European Union



Hartzema AG, Tilson HH, Chan KA. (2008). *Pharmacoepidemiology and Therapeutic Risk Management* (1st ed.). Harvey Whitney Books Company.

IEA Good Epidemiology Practice Guideline (GEP). (n.d.). Retrieved from <http://ieaweb.org/good-epidemiological-practice-gep/>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Parfrey PS, Barret BJ. (2016). *Clinical epidemiology: practice and methods* (2nd ed.). Human Press.

Porta M, Last JM, Greenland S. (2008). *A Dictionary of Epidemiology*. 5th Edition (5th Edition). Oxford University Press.

Rothman K, Greenland S, Lash T. (2008). *Modern Epidemiology* (3rd ed.). Lippincott Williams & Wilkins.

Strom B, Kimmel SE, Hennessy S. (2013). *Textbook of Pharmacoepidemiology* (2nd ed.). Wiley.

Woodward, M. (2014). *Epidemiology: Study Design and Data Analysis* (3rd ed.). Chapman & Hall.

References – Chapter 2

Brown, P., Brunnhuber, K., Chalkidou, K., Chalmers, I., Clarke, M., Fenton, M., Young, P. (2006). How to formulate research recommendations. *BMJ: British Medical Journal*, 333(7572), 804–806.

<https://doi.org/10.1136/bmj.38987.492014.94>

European Network of Health Technology Assessment (EUnetHTA). Position paper on how to formulate research recommendations. (n.d.). Retrieved from https://www.eunetha.eu/wp-content/uploads/2018/01/eunetha_position_paper_on_research_recommendations_0-1.pdf

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

References – Chapter 3

Agency for Healthcare Research and Quality (AHRQ). (n.d.). Retrieved April 5, 2018, from <https://www.ahrq.gov/>

AHRQ. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. (n.d.). Retrieved from <https://www.effectivehealthcare.ahrq.gov/topics/observational-cer-protocol/research>

Commission Implementing Regulation (EU) No 520/2012. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Directive 2001/20/EC of the European Parliament and of the Council. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF>

ENCePP Checklist for Study Protocols. (n.d.). Retrieved from http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml

European Medicines Agency. Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies. (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2013/01/WC500137939.pdf

European Medicines Agency. Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies. (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/10/WC500133174.pdf

FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

Guideline of good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c

Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Volume 10 - Clinical trials guidelines. (n.d.). Retrieved April 5, 2018, from <https://ec.europa.eu/health/documents/eudralex/vol-10/>

References – Chapter 4

Abenham, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Bégaud, B. (1996). Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. *New England Journal of Medicine*, 335(9), 609–616. <https://doi.org/10.1056/NEJM199608293350901>

ADVANCE project. (n.d.). Retrieved April 5, 2018, from <http://www.advance-vaccines.eu/?page=home>

Alvarez, Y., Hidalgo, A., Maignen, F., & Slattery, J. (2010). Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. *Drug Safety*, 33(6), 475–487. <https://doi.org/10.2165/11534410-000000000-00000>

American Association for Public Opinion Research (AAPOR). (n.d.). Retrieved April 5, 2018, from <https://www.aapor.org/>

American Association for Public Opinion Research (AAPOR). Standard Definitions. Final Dispositions of Case Codes and Outcome Rates for Surveys. (n.d.). Retrieved from https://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf

ARITMO project. (n.d.). Retrieved from <https://www.aritmo-project.org/?q=content/synapse>

Banerjee, A. K., & Ingate, S. (2012). Web-based patient-reported outcomes in Drug Safety and risk management: challenges and opportunities? *Drug Safety*, 35(6), 437–446. <https://doi.org/10.2165/11632390-000000000-00000>

Becker, B. F. H., Avillach, P., Romio, S., van Mulligen, E. M., Weibel, D., Sturkenboom, M. C. J. M., ... ADVANCE consortium. (2017). CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE project. *Pharmacoepidemiology and Drug Safety*, 26(8), 998–1005. <https://doi.org/10.1002/pds.4245>

Berger ML, Mamdani M, Atkins D, Johnson ML. (n.d.). Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartI.pdf>

Bhattacharya, M., Snyder, S., Malin, M., Truffa, M. M., Marinic, S., Engelmann, R., & Raheja, R. R. (2017). Using Social Media Data in Routine Pharmacovigilance: A Pilot Study to Identify Safety Signals and Patient Perspectives. *Pharmaceutical Medicine*, 31(3), 167–174. <https://doi.org/10.1007/s40290-017-0186-6>

- Bourke, A., Bate, A., Sauer, B. C., Brown, J. S., & Hall, G. C. (2016). Evidence generation from healthcare databases: recommendations for managing change. *Pharmacoepidemiology and Drug Safety*, 25(7), 749–754. <https://doi.org/10.1002/pds.4004>
- Bouvy, J. C., Blake, K., Slattery, J., De Bruin, M. L., Arlett, P., & Kurz, X. (2017). Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. *Pharmacoepidemiology and Drug Safety*, 26(12), 1442–1450. <https://doi.org/10.1002/pds.4196>
- Canadian Network for Observational Drug Effects Studies (CNODES). (n.d.). Retrieved April 5, 2018, from <https://www.cnodes.ca/>
- Charlton R, De Vries C. (n.d.). Systematic overview of data sources for Drug Safety in pregnancy research. Retrieved from http://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf
- CHMP Guideline on Conduct of Pharmacovigilance for Medicines Used by the Paediatric Population. (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003764.pdf
- CIOMS Working Group VIII Practical Aspects of Signal Detection in Pharmacovigilance. (n.d.). Retrieved April 5, 2018, from <https://cioms.ch/shop/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/>
- Clinical trials - Regulation EU No 536/2014. (n.d.). Retrieved July 3, 2018, from https://ec.europa.eu/health/human-use/clinical-trials/regulation_en
- Cocos, A., Fiks, A. G., & Masino, A. J. (2017). Deep learning for pharmacovigilance: recurrent neural network architectures for labeling adverse drug reactions in Twitter posts. *Journal of the American Medical Informatics Association: JAMIA*, 24(4), 813–821. <https://doi.org/10.1093/jamia/ocw180>
- Coloma, P. M., Becker, B., Sturkenboom, M. C. J. M., van Mulligen, E. M., & Kors, J. A. (2015). Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies. *Drug Safety*, 38(10), 921–930. <https://doi.org/10.1007/s40264-015-0333-5>
- Coloma, P. M., Schuemie, M. J., Trifirò, G., Gini, R., Herings, R., Hippisley-Cox, J., EU-ADR Consortium. (2011). Combining electronic healthcare databases in Europe to allow for large-scale Drug Safety monitoring: the EU-ADR Project. *Pharmacoepidemiology and Drug Safety*, 20(1), 1–11. <https://doi.org/10.1002/pds.2053>
- EMIF project. (n.d.). Retrieved April 5, 2018, from <http://www.emif.eu/>
- Emilsson, L., Lindahl, B., Köster, M., Lambe, M., & Ludvigsson, J. F. (2015). Review of 103 Swedish Healthcare Quality Registries. *Journal of Internal Medicine*, 277(1), 94–136. <https://doi.org/10.1111/joim.12303>
- ENCePP Database of Research Resources. (n.d.). Retrieved April 5, 2018, from <http://www.encepp.eu/encepp/resourcesDatabase.jsp>
- ENCePP Inventory of Data Sources. (n.d.). Retrieved April 5, 2018, from <http://www.encepp.eu/encepp/resourcesDatabase.jsp>
- EU General Data Protection Regulation (GDPR). (n.d.). Retrieved July 3, 2018, from <http://eugdpr.org/eugdpr.org-1.html>
- EU PARENT Joint Action. (n.d.). Retrieved April 5, 2018, from <http://parent-ror.eu/#/>
- EU-ADR project. (n.d.). Retrieved from <https://www.euadr-project.org/>
- EudraVigilance. (n.d.). Retrieved April 5, 2018, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WC0b01ac05800250b5
- EUnetHTA Joint Action 3. (n.d.). Retrieved April 5, 2018, from <https://www.eunetha.eu/ja3-archive/>

- EUROCAT. (n.d.). Retrieved April 5, 2018, from <http://www.eurocat-network.eu/>
- EUROmedICAT. (n.d.). Retrieved from <http://www.euromedicat.eu/>
- European Commission Digital Single Market Glossary. (n.d.). Retrieved July 3, 2018, from <https://ec.europa.eu/digital-single-market/en/glossary>
- European Medicines Agency - Patient registries. (n.d.). Retrieved June 13, 2018, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000658.jsp&mid=WC0b01ac0580961211
- European Medicines Agency (EMA). Guideline for good clinical practice E6(R2). (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf
- European Network and Information Security Agency (ENISA). (n.d.). [Plone Site]. Retrieved July 3, 2018, from <https://www.enisa.europa.eu/>
- European Union electronic Register of Post-Authorisation Studies (EU PAS Register). (n.d.). Retrieved April 5, 2018, from http://www.encepp.eu/encepp_studies/indexRegister.shtml
- Fayers PM, Machin D. (2007). Quality of Life: the assessment, analysis and interpretation of patient-related outcomes (2nd ed.). Wiley.
- FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>
- FDA Guidance for Industry: Establishing Pregnancy Exposure Registries. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf>
- FDA. Guidance for Industry - Establishing Pregnancy Exposure Registries. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf>
- FDA's Sentinel Initiative. (n.d.). [WebContent]. Retrieved April 5, 2018, from <https://www.fda.gov/safety/fdassentinelinitiative/ucm2007250.htm>
- Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M. (2015). Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. *BMJ: British Medical Journal*, 350, h1798. Retrieved from <http://www.bmj.com/content/bmj/350/bmj.h1798.full.pdf>
- German Society for Epidemiology (DGEpi). (n.d.). Retrieved April 5, 2018, from <https://www.dgepi.de/startseite.html>
- German Society for Epidemiology (DGEpi). Good Practice in Secondary Data Analysis Version 2. (n.d.). Retrieved from http://dgepi.de/fileadmin/pdf/leitlinien/gps-version2-final_ENG.pdf
- Gini, R., Schuemie, M., Brown, J., Ryan, P., Vacchi, E., Coppola, M., ... Sturkenboom, M. (2016). Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies. *EGEMS (Washington, DC)*, 4(1), 1189. <https://doi.org/10.13063/2327-9214.1189>
- GRIp network (Global Research in Paediatrics). (n.d.). Retrieved April 5, 2018, from <http://www.grip-network.org/index.php/cms/en/home>
- Groves RM, Fowler FJ, Couper MP et al. (2009). *Survey Methodology* (2nd ed.). Wiley.

Guideline of good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies. (n.d.). Retrieved from

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WCOB01ac058058f32c

Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products. (n.d.). Retrieved from

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WCOB01ac058058f32c

Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, Lo Casale R. (2012). Guidelines for Good Database Selection and use in Pharmacoepidemiology Research. *Pharmacoepidemiol Drug Saf*, (21), 1–10. Retrieved from

http://www.pharmacoepi.org/resources/Quality_Database_Conduct_2-28-11.pdf

Hennessy S, Bilker WB, Weber A, Strom BL. (n.d.). Descriptive analyses of the integrity of a US Medicaid claims Database. *Pharmacoepidemiol Drug Saf*, (12), 103–111. Retrieved from

<http://onlinelibrary.wiley.com/doi/10.1002/pds.765/pdf>

HMO Research Network (HMORN). (n.d.). Retrieved April 5, 2018, from

https://epi.grants.cancer.gov/pharm/pharmacoepi_db/hmorn.html

International Society for Pharmacoeconomics and Outcome Research (ISPOR). (n.d.). Retrieved April 5, 2018, from

<https://www.ispor.org/>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from

<https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Jollis, J. G. (1993). Discordance of Databases Designed for Claims Payment versus Clinical Information Systems: Implications for Outcomes Research. *Annals of Internal Medicine*, 119(8), 844. <https://doi.org/10.7326/0003-4819-119-8-199310150-00011>

Kaufman, D. W., Rosenberg, L., & Mitchell, A. A. (2001). Signal generation and clarification: use of case-control data. *Pharmacoepidemiology and Drug Safety*, 10(3), 197–203. <https://doi.org/10.1002/pds.571>

Kieler, H., Artama, M., Engeland, A., Ericsson, Ö., Furu, K., Gissler, M., ... Haglund, B. (2012). Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. *BMJ*, 344, d8012. <https://doi.org/10.1136/bmj.d8012>

Kish L. (1995). *Survey Sampling*. Wiley.

Klunigel, O. H., Kurz, X., Groot, M. C. H. de, Schlienger, R. G., Tcherny-Lessenot, S., Grimaldi, L., Reynolds, R. F. (n.d.). Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. *Pharmacoepidemiology and Drug Safety*, 25(S1), 156–165. <https://doi.org/10.1002/pds.3968>

Klunigel Olaf H., Kurz Xavier, Groot Mark C. H., Schlienger Raymond G., Tcherny-Lessenot Stephanie, Grimaldi Lamiae, Reynolds Robert F. (2016). Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. *Pharmacoepidemiology and Drug Safety*, 25(S1), 156–165. <https://doi.org/10.1002/pds.3968>

Lepkowski JM, Tucker NC, Bricket JM. (2007). *Advances in telephone survey methodology, Part V*. Wiley.

Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis | NEJM. (n.d.). Retrieved April 5, 2018, from <http://www.nejm.org/doi/full/10.1056/NEJM199512143332404>

Norwegian Patient Registry. (n.d.). Retrieved June 13, 2018, from <https://helsedirektoratet.no/english/norwegian-patient-registry>

Observational Health Data Sciences and Informatics (OHDSI). (n.d.). Retrieved April 5, 2018, from

<https://www.ohdsi.org/>

Observational Medical Outcomes Partnership (OMOP) CDM. (n.d.). Retrieved from <https://www.ohdsi.org/data-standardization/the-common-data-model/>

Opinion 1/2015 Mobile Health-Reconciling technological innovation with data protection. (n.d.). Retrieved from https://edps.europa.eu/sites/edp/files/publication/15-05-21_mhealth_en_0.pdf

Overhage, J. M., Ryan, P. B., Reich, C. G., Hartzema, A. G., & Stang, P. E. (2012). Validation of a common data model for active safety surveillance research. *Journal of the American Medical Informatics Association : JAMIA*, 19(1), 54–60. <https://doi.org/10.1136/amiainl-2011-000376>

Pacurariu, A., Plueschke, K., Olmo, C. A., & Kurz, X. (2018). Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.4449>

PARENT Joint Action. (n.d.). Retrieved April 5, 2018, from <http://parent-ror.eu/#/>

Pharmachild. (n.d.). Retrieved April 5, 2018, from <https://www.printo.it/projects/ongoing/15>

Powell, G. E., Seifert, H. A., Reblin, T., Burstein, P. J., Blowers, J., Menius, J. A., Dasgupta, N. (2016). Social Media Listening for Routine Post-Marketing Safety Surveillance. *Drug Safety*, 39(5), 443–454. <https://doi.org/10.1007/s40264-015-0385-6>

PROTECT project. (n.d.). Retrieved April 5, 2018, from <http://www.imi-protect.eu/about.shtml>

PROTECT project. Improving Consistency and Understanding of Discrepancies of Findings from Pharmacoepidemiological Studies: the IMI PROTECT Project. (n.d.). <https://doi.org/10.1002/pds.v25.S1>

Qualification opinion - The European Cystic Fibrosis Society Patient Registry (ECFSPR). (n.d.). Retrieved June 13, 2018, from http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=W500243542&murl=menus/document_library/document_library.jsp&mid=0b01ac058009a3dc

Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition. (n.d.). Retrieved August 3, 2018, from <https://effectivehealthcare.ahrq.gov/topics/registries-guide-3rd-edition-addendum/overview>

Roberto, G., Leal, I., Sattar, N., Loomis, A. K., Avillach, P., Egger, P., Gini, R. (2016). Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. *PLoS One*, 11(8), e0160648. <https://doi.org/10.1371/journal.pone.0160648>

SAFEGUARD project. (n.d.). Retrieved April 5, 2018, from <http://www.safeguardproject.info/>

Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015). The Danish National Patient Registry: a review of content, data quality, and research potential. *Clinical Epidemiology*, 7, 449–490. <https://doi.org/10.2147/CLEP.S91125>

Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*, 58(4), 323–337. <https://doi.org/10.1016/j.jclinepi.2004.10.012>

Shapiro, S. (1983). The design of a study of the drug etiology of agranulocytosis and aplastic anemia. *European Journal of Clinical Pharmacology*, 24(6), 833–836. <https://doi.org/10.1007/BF00607096>

Sloane, R., Osanlou, O., Lewis, D., Bollegala, D., Maskell, S., & Pirmohamed, M. (2015). Social media and pharmacovigilance: A review of the opportunities and challenges. *British Journal of Clinical Pharmacology*, 80(4), 910–920. <https://doi.org/10.1111/bcp.12717>

Smartphone Secure Development Guidelines. (n.d.). Retrieved from http://www.enisa.europa.eu/activities/Resilience-and-CIIP/critical-applications/smartphone-security-1/smartphone-secure-development-guidelines/at_download/fullReport

- SOS project. (n.d.). Retrieved April 5, 2018, from <https://www.sos-nsaids-project.org/>
- Streiner DL, Norman GR. (2008). Health Measurement Scales: a practical guide to their development and use (4th ed.). Oxford University Press.
- Strom B, Kimmel SE, Hennessy S. (2012). Pharmacoepidemiology (5th ed.). Wiley.
- Swedish National Patient Register. (n.d.). Retrieved April 5, 2018, from <http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish>
- The Innovative Medicines Initiative (IMI). (n.d.). Retrieved June 26, 2018, from <http://www.imi.europa.eu/>
- The U.S. Food and Drug Administration's Mini-Sentinel Program. (n.d.). Retrieved April 5, 2018, from <https://onlinelibrary.wiley.com/toc/10991557/21/S1>
- Tregunno, P. M., Fink, D. B., Fernandez-Fernandez, C., Lázaro-Bengoa, E., & Norén, G. N. (2014). Performance of probabilistic method to detect duplicate individual case safety reports. *Drug Safety*, 37(4), 249–258. <https://doi.org/10.1007/s40264-014-0146-y>
- Trifirò, G., Coloma, P. M., Rijnbeek, P. R., Romio, S., Mosseveld, B., Weibel, D., Sturkenboom, M. (2014). Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? *Journal of Internal Medicine*, 275(6), 551–561. <https://doi.org/10.1111/joim.12159>
- UK Renal Registry. (n.d.). Retrieved April 5, 2018, from <https://www.renalreg.org/about-us/>
- Vaccine Safety Datalink (VSD). (2018, March 2). Retrieved June 26, 2018, from <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>
- Vander Stichele R. H., Elseviers M. M., Ferech M., Blot S., Goossens H., & null null. (2004). European Surveillance of Antimicrobial Consumption (ESAC): Data Collection Performance and Methodological Approach. *British Journal of Clinical Pharmacology*, 58(4), 419–428. <https://doi.org/10.1111/j.1365-2125.2004.02164.x>
- Verstraeten, T., DeStefano, F., Chen, R. T., & Miller, E. (2003). Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. *Expert Review of Vaccines*, 2(1), 21–29. <https://doi.org/10.1586/14760584.2.1.21>
- Volume 10 - Clinical trials guidelines. (n.d.). Retrieved June 13, 2018, from <https://ec.europa.eu/health/documents/eudralex/vol-10/>
- WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Classification System. (n.d.). Retrieved April 5, 2018, from https://www.whocc.no/atc/structure_and_principles/
- WHO Collaborating Centre for Drug Statistics Methodology. Defined Daily Doses. (n.d.). Retrieved April 5, 2018, from https://www.whocc.no/ddd/definition_and_general_considera/
- WHO. The Global Individual Case Safety Reports Database System (VigiBase). (n.d.). Retrieved April 5, 2018, from <https://www.who-umc.org/vigibase/vigibase/>
- Wisniewski AFZ, Juhlin K, Vestergaard Laursen M, Macia MM, Manlik K, Pinkston VK, Seabroke S, Slattery J (PROTECT project). (n.d.). Characterization of databases (DB) used for signal detection (SD). Retrieved from <http://www.imi-protect.eu/documents/WisniewskietalCharacterisationofdatabasesusedorsignaldetectionposterfinalICPE2012.pdf>
- Xu, Y., Zhou, X., Suehs, B. T., Hartzema, A. G., Kahn, M. G., Moride, Y., Bate, A. (2015). A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. *Drug Safety*, 38(8), 749–765. <https://doi.org/10.1007/s40264-015-0297-5>

References – Chapter 5

- Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Pestman, W. R., Hoes, A. W., Roes, K. C. B., Klungel, O. H. (2015). Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *Journal of Clinical Epidemiology*, 68(2), 112–121. <https://doi.org/10.1016/j.jclinepi.2014.08.011>
- Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Roes, K. C. B., Hoes, A. W., Klungel, O. H. (2014). Propensity score balance measures in pharmacoepidemiology: a simulation study. *Pharmacoepidemiology and Drug Safety*, 23(8), 802–811. <https://doi.org/10.1002/pds.3574>
- Ali, M. S., Uddin, M. J., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., Klungel, O. H. (2014). Quantitative falsification of instrumental variables assumption using balance measures. *Epidemiology (Cambridge, Mass.)*, 25(5), 770–772. <https://doi.org/10.1097/EDE.0000000000000152>
- Altman, D. G., & Bland, J. M. (2003). Interaction revisited: the difference between two estimates. *BMJ (Clinical Research Ed.)*, 326(7382), 219. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1125071/>
- Arbogast, P. G., & Ray, W. A. (2009). Use of disease risk scores in pharmacoepidemiologic studies. *Statistical Methods in Medical Research*, 18(1), 67–80. <https://doi.org/10.1177/0962280208092347>
- Baiocchi, M., Cheng, J., & Small, D. S. (2014). Instrumental variable methods for causal inference. *Statistics in Medicine*, 33(13), 2297–2340. <https://doi.org/10.1002/sim.6128>
- Bate A., & Evans S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiology and Drug Safety*, 18(6), 427–436. <https://doi.org/10.1002/pds.1742>
- Belitser, S. V., Martens, E. P., Pestman, W. R., Groenwold, R. H. H., de Boer, A., & Klungel, O. H. (2011). Measuring balance and model selection in propensity score methods. *Pharmacoepidemiology and Drug Safety*, 20(11), 1115–1129. <https://doi.org/10.1002/pds.2188>
- Berlin, C., Blanch, C., Lewis, D. J., Maladorno, D. D., Michel, C., Petrin, M., Close, P. (2012). Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. *Pharmacoepidemiology and Drug Safety*, 21(6), 622–630. <https://doi.org/10.1002/pds.2247>
- Brenner, H., & Gefeller, O. (1993). Use of the Positive Predictive Value to Correct for Disease Misclassification in Epidemiologic Studies. *American Journal of Epidemiology*, 138(11), 1007–1015. <https://doi.org/10.1093/oxfordjournals.aje.a116805>
- Brighton Collaboration. Case definitions. (n.d.). Retrieved from <https://www.brightoncollaboration.org/activities/scientific-priority-areas.html>
- Brookhart, M. A., Wang, P., Solomon, D. H., & Schneeweiss, S. (2006). Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. *Epidemiology (Cambridge, Mass.)*, 17(3), 268–275. <https://doi.org/10.1097/01.ede.0000193606.58671.c5>
- Brookhart M. Alan, Rassen Jeremy A., & Schneeweiss Sebastian. (2010). Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidemiology and Drug Safety*, 19(6), 537–554. <https://doi.org/10.1002/pds.1908>
- Brunelli, S. M., Gagne, J. J., Huybrechts, K. F., Wang, S. V., Patrick, A. R., Rothman, K. J., & Seeger, J. D. (2013). Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. *Pharmacoepidemiology and Drug Safety*, 22(5), 542–550. <https://doi.org/10.1002/pds.3434>
- Candore, G., Juhlin, K., Manlik, K., Thakrar, B., Quarcio, N., Seabroke, S., Slattery, J. (2015). Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases. *Drug Safety*, 38(6), 577–587. <https://doi.org/10.1007/s40264-015-0289-5>

- Carnahan, R. M., & Moores, K. G. (2012). Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned. *Pharmacoepidemiology and Drug Safety*, 21 Suppl 1, 82–89. <https://doi.org/10.1002/pds.2321>
- Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. (n.d.). Retrieved April 6, 2018, from <https://academic.oup.com/aje/article-abstract/133/2/144/118507>
- Caster, O., Juhlin, K., Watson, S., & Norén, G. N. (2014). Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. *Drug Safety*, 37(8), 617–628. <https://doi.org/10.1007/s40264-014-0204-5>
- Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2013). Logistic regression in signal detection: another piece added to the puzzle. *Clinical Pharmacology and Therapeutics*, 94(3), 312. <https://doi.org/10.1038/clpt.2013.107>
- Caster Ola, Norén G. Niklas, Madigan David, & Bate Andrew. (2010). Large-scale regression-based pattern discovery: The example of screening the WHO global Drug Safety database. *Statistical Analysis and Data Mining: The ASA Data Science Journal*, 3(4), 197–208. <https://doi.org/10.1002/sam.10078>
- Chou, R. (2005). Challenges in Systematic Reviews That Assess Treatment Harms. *Annals of Internal Medicine*, 142(12_Part_2), 1090. https://doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00009
- CIOMS Working Group VIII Practical Aspects of Signal Detection in Pharmacovigilance. (n.d.). Retrieved April 5, 2018, from <https://cioms.ch/shop/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/>
- CIOMS Working Group X. Guideline on Evidence Synthesis and Meta-Analysis for Drug Safety. (n.d.). Retrieved April 5, 2018, from https://cioms.ch/working_groups/working-group-x/
- ClinicalCodes.org. (n.d.). Retrieved April 5, 2018, from <https://clinicalcodes.rss.mhs.man.ac.uk/>
- Cole, S. R., Hernán, M. A., Robins, J. M., Anastos, K., Chmiel, J., Detels, R., ... Muñoz, A. (2003). Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. *American Journal of Epidemiology*, 158(7), 687–694. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/14507605>
- Collier, S., Harvey, C., Brewster, J., Bakerly, N. D., Elkhenini, H. F., Stanciu, R., Leather, D. (2017). Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study. *Pharmacoepidemiology and Drug Safety*, 26(3), 344–352. <https://doi.org/10.1002/pds.4118>
- Daniel, R. M., Cousens, S. N., De Stavola, B. L., Kenward, M. G., & Sterne, J. a. C. (2013). Methods for dealing with time-dependent confounding. *Statistics in Medicine*, 32(9), 1584–1618. <https://doi.org/10.1002/sim.5686>
- Data mining for signals in spontaneous reporting databases: proceed with caution - Stephenson - 2007 - *Pharmacoepidemiology and Drug Safety* - Wiley Online Library. (n.d.). Retrieved April 6, 2018, from <https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.1323>
- Data-Driven Prediction of Drug Effects and Interactions | *Science Translational Medicine*. (n.d.). Retrieved April 6, 2018, from <http://stm.sciencemag.org/content/4/125/125ra31>
- Davé, S., & Petersen, I. (2009). Creating medical and drug code lists to identify cases in primary care databases. *Pharmacoepidemiology and Drug Safety*, 18(8), 704–707. <https://doi.org/10.1002/pds.1770>
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital Department of Medicine. *Pharmacoepidemiology Toolbox*. (n.d.). Retrieved April 5, 2018, from <http://www.drugapi.org/dope-downloads/>
- Dormuth, C. R., Patrick, A. R., Shrank, W. H., Wright, J. M., Glynn, R. J., Sutherland, J., & Brookhart, M. A. (2009). Statin adherence and risk of accidents: a cautionary tale. *Circulation*, 119(15), 2051–2057. <https://doi.org/10.1161/CIRCULATIONAHA.108.824151>

- DuMouchel, W., Yuen, N., Payvandi, N., Booth, W., Rut, A., & Fram, D. (2013). Automated method for detecting increases in frequency of spontaneous adverse event reports over time. *Journal of Biopharmaceutical Statistics*, 23(1), 161–177. <https://doi.org/10.1080/10543406.2013.736809>
- Dusetzina, S. B., Brookhart, M. A., & Maciejewski, M. L. (2015). Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. *Health Services Research*, 50(5), 1432–1451. <https://doi.org/10.1111/1475-6773.12279>
- Elseviers M, Wettermark B, Almarsdóttir AB, et al. (2016). *Drug Utilization Research: Methods and Applications*. Wiley Blackwell.
- Elseviers M, Wettermark B, Almarsdóttir AB et al. (2016). *Methods and Applications*. Wiley Blackwell.
- ENCePP Database of Research Resources. (n.d.). Retrieved April 5, 2018, from <http://www.encepp.eu/encepp/resourcesDatabase.jsp>
- EudraVigilance. (n.d.). Retrieved April 5, 2018, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WCOb01ac05800250b5
- European Medicines Agency. Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system. (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011434.pdf
- Farrington, C. P. (2004). Control without separate controls: evaluation of vaccine safety using case-only methods. *Vaccine*, 22(15–16), 2064–2070. <https://doi.org/10.1016/j.vaccine.2004.01.017>
- Farrington, C. P., Whitaker, H. J., & Hocine, M. N. (2009). Case series analysis for censored, perturbed, or curtailed post-event exposures. *Biostatistics (Oxford, England)*, 10(1), 3–16. <https://doi.org/10.1093/biostatistics/kxn013>
- FDA's Sentinel Initiative. (n.d.). [WebContent]. Retrieved April 5, 2018, from <https://www.fda.gov/safety/fdassentinelinitiative/ucm2007250.htm>
- Fewell, Z., Davey Smith, G., & Sterne, J. A. C. (2007). The Impact of Residual and Unmeasured Confounding in Epidemiologic Studies: A Simulation Study. *American Journal of Epidemiology*, 166(6), 646–655. <https://doi.org/10.1093/aje/kwm165>
- Franklin, J. M., Rassen, J. A., Ackermann, D., Bartels, D. B., & Schneeweiss, S. (2014). Metrics for covariate balance in cohort studies of causal effects. *Statistics in Medicine*, 33(10), 1685–1699. <https://doi.org/10.1002/sim.6058>
- Fröbert, O., Lagerqvist, B., Olivecrona, G. K., Omerovic, E., Gudnason, T., Maeng, M., James, S. K. (2013). Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. *New England Journal of Medicine*, 369(17), 1587–1597. <https://doi.org/10.1056/NEJMoa1308789>
- Garabedian, L. F., Chu, P., Toh, S., Zaslavsky, A. M., & Soumerai, S. B. (2014). Potential bias of instrumental variable analyses for observational comparative effectiveness research. *Annals of Internal Medicine*, 161(2), 131–138. <https://doi.org/10.7326/M13-1887>
- Gerhard, T. (2008). Bias: considerations for research practice. *American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists*, 65(22), 2159–2168. <https://doi.org/10.2146/ajhp070369>
- GetReal project. Glossary of Definitions of Common Terms. (n.d.). Retrieved from https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf

- Glynn, R. J., Gagne, J. J., & Schneeweiss, S. (2012). Role of disease risk scores in comparative effectiveness research with emerging therapies. *Pharmacoepidemiology and Drug Safety*, 21 Suppl 2, 138–147. <https://doi.org/10.1002/pds.3231>
- Greenland, S. (1996). Basic Methods for Sensitivity Analysis of Biases. *International Journal of Epidemiology*, 25(6), 1107–1116. <https://doi.org/10.1093/ije/25.6.1107-a>
- Greenland, S. (1996). Confounding and exposure trends in case-crossover and case-time-control designs. *Epidemiology (Cambridge, Mass.)*, 7(3), 231–239. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8728434>
- Greenland, S. (2000). An introduction to instrumental variables for epidemiologists. *International Journal of Epidemiology*, 29(4), 722–729. <https://doi.org/10.1093/ije/29.4.722>
- Grobbée, D. E., & Hoes, A. W. (1997). Confounding and indication for treatment in evaluation of drug treatment for hypertension. *BMJ*, 315(7116), 1151–1154. <https://doi.org/10.1136/bmj.315.7116.1151>
- Groenwold, R. H. H., de Vries, F., de Boer, A., Pestman, W. R., Rutten, F. H., Hoes, A. W., & Klungel, O. H. (2011). Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and Drug Safety*, 20(11), 1130–1137. <https://doi.org/10.1002/pds.2251>
- Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071696.pdf>
- Guideline on good pharmacovigilance practices (GVP) Module IX - Signal Management. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c
- Gulmez, S. E., Larrey, D., Pageaux, G.-P., Lignot, S., Lassalle, R., Jové, J., Moore, N. (2013). Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. *Drug Safety*, 36(2), 135–144. <https://doi.org/10.1007/s40264-012-0013-7>
- Hallas, J. (1996). Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. *Epidemiology (Cambridge, Mass.)*, 7(5), 478–484. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8862977>
- Hallas, J., & Pottegård, A. (2014). Use of self-controlled designs in pharmacoepidemiology. *Journal of Internal Medicine*, 275(6), 581–589. <https://doi.org/10.1111/joim.12186>
- Hallas, J., Pottegård, A., Wang, S., Schneeweiss, S., & Gagne, J. J. (2016). Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. *American Journal of Epidemiology*, 184(10), 761–769. <https://doi.org/10.1093/aje/kww079>
- Harpaz, R., DuMouchel, W., LePendou, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H. (2013). Performance of Pharmacovigilance Signal Detection Algorithms for the FDA Adverse Event Reporting System. *Clinical Pharmacology and Therapeutics*, 93(6). <https://doi.org/10.1038/clpt.2013.24>
- Hauben, M., Aronson, J. K., & Ferner, R. E. (2016). Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard “Negative Controls” by the Observational Medical Outcomes Partnership (OMOP). *Drug Safety*, 39(5), 421–432. <https://doi.org/10.1007/s40264-016-0392-2>
- Hauben, M., Madigan, D., Gerrits, C. M., Walsh, L., & Van Puijenbroek, E. P. (2005). The role of data mining in pharmacovigilance. *Expert Opinion on Drug Safety*, 4(5), 929–948. <https://doi.org/10.1517/14740338.4.5.929>
- Haut, E. R., & Pronovost, P. J. (2011). Surveillance Bias in Outcomes Reporting. *JAMA*, 305(23), 2462–2463. <https://doi.org/10.1001/jama.2011.822>

- Henry, D., Lim, L. L.-Y., Rodriguez, L. A. G., Gutthann, S. P., Carson, J. L., Griffin, M., ... Fries, J. T. (1996). Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. *BMJ*, 312(7046), 1563–1566. <https://doi.org/10.1136/bmj.312.7046.1563>
- Hernán, M. A., Brumback, B., & Robins, J. M. (2000). Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology (Cambridge, Mass.)*, 11(5), 561–570. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10955409>
- Horwitz, R. I., & Feinstein, A. R. (1978). Alternative Analytic Methods for Case-Control Studies of Estrogens and Endometrial Cancer. *New England Journal of Medicine*, 299(20), 1089–1094. <https://doi.org/10.1056/NEJM197811162992001>
- Immortal time bias in observational studies of drug effects - Suissa - 2007 - *Pharmacoepidemiology and Drug Safety* - Wiley Online Library. (n.d.). Retrieved April 6, 2018, from <https://academic.oup.com/aje/article/167/4/492/233064>
- Joffe, M. M., & Rosenbaum, P. R. (1999). Invited commentary: propensity scores. *American Journal of Epidemiology*, 150(4), 327–333. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10453808>
- Joffe Marshall M. (2000). Confounding by indication: the case of calcium channel blockers. *Pharmacoepidemiology and Drug Safety*, 9(1), 37–41. [https://doi.org/10.1002/\(SICI\)1099-1557\(200001/02\)9:1<37::AID-PDS471>3.0.CO;2-U](https://doi.org/10.1002/(SICI)1099-1557(200001/02)9:1<37::AID-PDS471>3.0.CO;2-U)
- Juhlin, K., Karimi, G., Andér, M., Camilli, S., Dheda, M., Har, T. S., Norén, G. N. (2015). Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites. *Drug Safety*, 38(4), 373–382. <https://doi.org/10.1007/s40264-015-0271-2>
- Juhlin, K., Ye, X., Star, K., & Norén, G. N. (2013). Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy. *Pharmacoepidemiology and Drug Safety*, 22(10), 1119–1129. <https://doi.org/10.1002/pds.3474>
- Khan, N. F., Harrison, S. E., & Rose, P. W. (2010). Validity of diagnostic coding within the General Practice Research Database: a systematic review. *The British Journal of General Practice: The Journal of the Royal College of General Practitioners*, 60(572), e128-136. <https://doi.org/10.3399/bjgp10X483562>
- Kiri, V. A., & MacKenzie, G. (2009). RE: "IMMORTAL TIME BIAS IN PHARMACOEPIDEMIOLOGY." *American Journal of Epidemiology*, 170(5), 667–668. <https://doi.org/10.1093/aje/kwp239>
- Klungle, O. H., Martens, E. P., Psaty, B. M., Grobbee, D. E., Sullivan, S. D., Stricker, B. H. C., ... de Boer, A. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. *Journal of Clinical Epidemiology*, 57(12), 1223–1231. <https://doi.org/10.1016/j.jclinepi.2004.03.011>
- Knol, M. J., & VanderWeele, T. J. (2012). Recommendations for presenting analyses of effect modification and interaction. *International Journal of Epidemiology*, 41(2), 514–520. <https://doi.org/10.1093/ije/dyr218>
- Knol, M. J., VanderWeele, T. J., Groenwold, R. H. H., Klungle, O. H., Rovers, M. M., & Grobbee, D. E. (2011). Estimating measures of interaction on an additive scale for preventive exposures. *European Journal of Epidemiology*, 26(6), 433–438. <https://doi.org/10.1007/s10654-011-9554-9>
- Lash, T. L., Fox, M. P., MacLehose, R. F., Maldonado, G., McCandless, L. C., & Greenland, S. (2014). Good practices for quantitative bias analysis. *International Journal of Epidemiology*, 43(6), 1969–1985. <https://doi.org/10.1093/ije/dyu149>
- Lauer, M. S., & D'Agostino, R. B. (2013). The randomized registry trial--the next disruptive technology in clinical research? *The New England Journal of Medicine*, 369(17), 1579–1581. <https://doi.org/10.1056/NEJMp1310102>
- Lawlor, D. A., Tilling, K., & Davey Smith, G. (2016). Triangulation in aetiological epidemiology. *International Journal of Epidemiology*, 45(6), 1866–1886. <https://doi.org/10.1093/ije/dyw314>

- Lee, W.-J., Lee, T. A., Pickard, A. S., Shoaibi, A., & Schumock, G. T. (2015). Using linked electronic data to validate algorithms for health outcomes in administrative databases. *Journal of Comparative Effectiveness Research*, 4(4), 359–366. <https://doi.org/10.2217/cer.15.14>
- Lesko, S. M., & Mitchell, A. A. (1995). An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. *JAMA*, 273(12), 929–933. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7884951>
- Lévesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010). Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *BMJ*, 340, b5087. <https://doi.org/10.1136/bmj.b5087>
- Lewis, M. A. (1999). The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect. *Human Reproduction Update*, 5(6), 707–720. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10652980>
- Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015). The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ*, 350, h2147. <https://doi.org/10.1136/bmj.h2147>
- Low, Y. S., Caster, O., Bergvall, T., Fourches, D., Zang, X., Norén, G. N., Tropsha, A. (2016). Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome. *Journal of the American Medical Informatics Association: JAMIA*, 23(5), 968–978. <https://doi.org/10.1093/jamia/ocv127>
- Lund, J. L., Richardson, D. B., & Stürmer, T. (2015). The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Current Epidemiology Reports*, 2(4), 221–228. <https://doi.org/10.1007/s40471-015-0053-5>
- Maclure, M. (1991). The case-crossover design: a method for studying transient effects on the risk of acute events. *American Journal of Epidemiology*, 133(2), 144–153.
- Maclure, M., Fireman, B., Nelson, J. C., Hua, W., Shoaibi, A., Paredes, A., & Madigan, D. (2012). When should case-only designs be used for safety monitoring of medical products? *Pharmacoepidemiology and Drug Safety*, 21 Suppl 1, 50–61. <https://doi.org/10.1002/pds.2330>
- Maignen, F., Hauben, M., Hung, E., Holle, L. V., & Dogne, J.-M. (2014). A conceptual approach to the masking effect of measures of disproportionality. *Pharmacoepidemiology and Drug Safety*, 23(2), 208–217. <https://doi.org/10.1002/pds.3530>
- Maignen, F., Hauben, M., Hung, E., Van Holle, L., & Dogne, J.-M. (2014). Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. *Pharmacoepidemiology and Drug Safety*, 23(2), 195–207. <https://doi.org/10.1002/pds.3529>
- Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S. V., & Klungel, O. H. (2006). Instrumental variables: application and limitations. *Epidemiology (Cambridge, Mass.)*, 17(3), 260–267. <https://doi.org/10.1097/01.ede.0000215160.88317.cb>
- McMahon AD. (2003). Approaches to combat with confounding by indication in observational studies of intended drug effects. *Pharmacoepidemiology and Drug Safety*, (12), 551–558. Retrieved from <https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.883>
- Medical Dictionary for Regulatory Activities (MedDRA). (n.d.). Retrieved April 6, 2018, from <https://www.meddra.org/>
- Miettinen, O. S. (1976). STRATIFICATION BY A MULTIVARIATE CONFOUNDER SCORE. *American Journal of Epidemiology*, 104(6), 609–620. <https://doi.org/10.1093/oxfordjournals.aje.a112339>
- Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Consolidated Standards of Reporting Trials Group. (2010). CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *Journal of Clinical Epidemiology*, 63(8), e1-37. <https://doi.org/10.1016/j.jclinepi.2010.03.004>

- Moodie, E. E. M., & Stephens, D. A. (2010). Using Directed Acyclic Graphs to detect limitations of traditional regression in longitudinal studies. *International Journal of Public Health*, 55(6), 701–703. <https://doi.org/10.1007/s00038-010-0184-x>
- Moore, N., Gulmez, S. E., Larrey, D., Pageaux, G.-P., Lignot, S., Lassalle, R., Bégaud, B. (2013). Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. *Pharmacoepidemiology and Drug Safety*, 22(2), 160–167. <https://doi.org/10.1002/pds.3371>
- Moride, Y., Abenhaim, L., Yola, M., & Lucein, A. (1994). Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. *Journal of Clinical Epidemiology*, 47(7), 731–737. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7722586>
- Nicholas, J. M., Grieve, A. P., & Gulliford, M. C. (2012). Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs. *Journal of Clinical Epidemiology*, 65(4), 384–393. <https://doi.org/10.1016/j.jclinepi.2011.09.004>
- Norén, G. N., & Edwards, I. R. (2009). Modern methods of pharmacovigilance: detecting adverse effects of drugs. *Clinical Medicine*, 9(5), 486–489. <https://doi.org/10.7861/clinmedicine.9-5-486>
- Observational Health Data Sciences and Informatics (OHDSI). (n.d.). Retrieved April 5, 2018, from <https://www.ohdsi.org/>
- Observational Medical Outcomes Partnership OMOP. (n.d.). Retrieved from <http://omop.org/>
- OMOP Common Data Model – OHDSI. (n.d.). Retrieved April 6, 2018, from <https://www.ohdsi.org/data-standardization/the-common-data-model/>
- Pinheiro, L. C., Candore, G., Zaccaria, C., Slattery, J., & Arlett, P. (2018). An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance. *Pharmacoepidemiology and Drug Safety*, 27(1), 38–45. <https://doi.org/10.1002/pds.4344>
- Pottegård, A., Christensen, R. dePont, Houji, A., Christiansen, C. B., Paulsen, M. S., Thomsen, J. L., & Hallas, J. (2014). Primary non-adherence in general practice: a Danish register study. *European Journal of Clinical Pharmacology*, 70(6), 757–763. <https://doi.org/10.1007/s00228-014-1677-y>
- PROTECT project. (n.d.). Retrieved April 5, 2018, from <http://www.imi-protect.eu/about.shtml>
- PROTECT project. Database of adverse drug reactions (EU SPC ADR database). (n.d.). Retrieved April 6, 2018, from <http://www.imi-protect.eu/methodsRep.shtml>
- PROTECT project. Inventory of Drug Consumption Databases in Europe. (n.d.). Retrieved April 6, 2018, from <http://www.imi-protect.eu/drugConsumption.shtml>
- Quantitative Bias Analysis Methodology Development: Sequential Bias Adjustment for Outcome Misclassification. (n.d.). Retrieved from https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel_Methods_Sequential_bias.pdf
- Rao, S. V., Hess, C. N., Barham, B., Aberle, L. H., Anstrom, K. J., Patel, T. B., Krucoff, M. W. (2014). A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. *JACC. Cardiovascular Interventions*, 7(8), 857–867. <https://doi.org/10.1016/j.jcin.2014.04.007>
- Rassen, J. A., Glynn, R. J., Brookhart, M. A., & Schneeweiss, S. (2011). Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. *American Journal of Epidemiology*, 173(12), 1404–1413. <https://doi.org/10.1093/aje/kwr001>

Rassen, J. A., & Schneeweiss, S. (2012). Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. *Journal of Comparative Effectiveness Research*, 1(2), 109–111.

<https://doi.org/10.2217/cer.12.12>

Rassen, J. A., Shelat, A. A., Franklin, J. M., Glynn, R. J., Solomon, D. H., & Schneeweiss, S. (2013). Matching by propensity score in cohort studies with three treatment groups. *Epidemiology (Cambridge, Mass.)*, 24(3), 401–409.

<https://doi.org/10.1097/EDE.0b013e318289dedf>

Rassen, J. A., Shelat, A. A., Myers, J., Glynn, R. J., Rothman, K. J., & Schneeweiss, S. (2012). One-to-many propensity score matching in cohort studies. *Pharmacoepidemiology and Drug Safety*, 21 Suppl 2, 69–80.

<https://doi.org/10.1002/pds.3263>

Rassen Jeremy A., & Schneeweiss Sebastian. (2012). Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. *Pharmacoepidemiology and Drug Safety*, 21(S1), 41–49. <https://doi.org/10.1002/pds.2328>

Ray, W. A. (2003). Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. *American Journal of Epidemiology*, 158(9), 915–920. <https://doi.org/10.1093/aje/kwg231>

Robins, J. M., Hernán, M. A., & Brumback, B. (2000). Marginal structural models and causal inference in epidemiology. *Epidemiology (Cambridge, Mass.)*, 11(5), 550–560. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10955408>

Rothman K, Greenland S, Lash T. (2008). *Modern Epidemiology* (3rd ed.). Lippincott Williams & Wilkins.

Routine signal detection methods in EudraVigilance. (n.d.). Retrieved from

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/12/WC500218606.pdf

Salvo, F., Leborgne, F., Thiessard, F., Moore, N., Bégaud, B., & Pariente, A. (2013). A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. *Drug Safety*, 36(7), 565–572. <https://doi.org/10.1007/s40264-013-0063-5>

Sanni Ali, M., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., de Boer, A., & Klungel, O. H. (2013). Time-dependent propensity score and collider-stratification bias: an example of beta2-agonist use and the risk of coronary heart disease. *European Journal of Epidemiology*, 28(4), 291–299. <https://doi.org/10.1007/s10654-013-9766-2>

Schmidt, A. F., Groenwold, R. H. H., Knol, M. J., Hoes, A. W., Nielen, M., Roes, K. C. B., Klungel, O. H. (2014). Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. *Journal of Clinical Epidemiology*, 67(7), 821–829.

<https://doi.org/10.1016/j.jclinepi.2014.02.008>

Schmidt, A. F., Klungel, O. H., Groenwold, R. H. H., & GetReal Consortium. (2016). Adjusting for Confounding in Early Postlaunch Settings: Going Beyond Logistic Regression Models. *Epidemiology (Cambridge, Mass.)*, 27(1), 133–142.

<https://doi.org/10.1097/EDE.0000000000000388>

Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*, 58(4), 323–337. <https://doi.org/10.1016/j.jclinepi.2004.10.012>

Schneeweiss, S., Gagne, J. J., Glynn, R. J., Ruhl, M., & Rassen, J. A. (2011). Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. *Clinical Pharmacology and Therapeutics*, 90(6), 777–790. <https://doi.org/10.1038/clpt.2011.235>

Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009). High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology (Cambridge, Mass.)*, 20(4), 512–522. <https://doi.org/10.1097/EDE.0b013e3181a663cc>

Schneeweiss, S., Stürmer, T., & Maclure, M. (1997). Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. *Pharmacoepidemiology and Drug Safety*, 6 Suppl 3, S51-59.

[https://doi.org/10.1002/\(SICI\)1099-1557\(199710\)6:3+<S51::AID-PDS301>3.0.CO;2-S](https://doi.org/10.1002/(SICI)1099-1557(199710)6:3+<S51::AID-PDS301>3.0.CO;2-S)

Schneeweiss Sebastian. (2006). Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. *Pharmacoepidemiology and Drug Safety*, 15(5), 291–303.

<https://doi.org/10.1002/pds.1200>

Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D., & Suchard, M. A. (2016). Robust empirical calibration of p-values using observational data. *Statistics in Medicine*, 35(22), 3883–3888. <https://doi.org/10.1002/sim.6977>

Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D., & Suchard, M. A. (2018). Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. *Proceedings of the National Academy of Sciences of the United States of America*, 115(11), 2571–2577.

<https://doi.org/10.1073/pnas.1708282114>

Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A., & Madigan, D. (2014). Interpreting observational studies: why empirical calibration is needed to correct p-values. *Statistics in Medicine*, 33(2), 209–218.

<https://doi.org/10.1002/sim.5925>

Seabroke, S., Candore, G., Juhlin, K., Quarcoo, N., Wisniewski, A., Arani, R., Slattery, J. (2016). Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases. *Drug Safety*, 39(4), 355–364.

<https://doi.org/10.1007/s40264-015-0388-3>

Self Controlled Case Series Method Website. (n.d.). Retrieved from <http://statistics.open.ac.uk/sccs>

Shrank, W. H., Patrick, A. R., & Brookhart, M. A. (2011). Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. *Journal of General Internal Medicine*, 26(5), 546–550.

<https://doi.org/10.1007/s11606-010-1609-1>

Staa, T.-P. van, Goldacre, B., Gulliford, M., Cassell, J., Pirmohamed, M., Taweel, A., Smeeth, L. (2012). Pragmatic randomised trials using routine electronic health records: putting them to the test. *BMJ*, 344, e55.

<https://doi.org/10.1136/bmj.e55>

Strom B, Kimmel SE, Hennessy S. (2012). *Pharmacoepidemiology* (5th ed.). Wiley.

Strom, B. L., Eng, S. M., Faich, G., Reynolds, R. F., D'Agostino, R. B., Ruskin, J., & Kane, J. M. (2011). Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). *The American Journal of Psychiatry*, 168(2), 193–201.

<https://doi.org/10.1176/appi.ajp.2010.08040484>

Stürmer, T., Glynn, R. J., Rothman, K. J., Avorn, J., & Schneeweiss, S. (2007). Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. *Medical Care*, 45(10 SUPPL), S158–S165.

<https://doi.org/10.1097/MLR.0b013e318070c045>

Stürmer, T., Rothman, K. J., Avorn, J., & Glynn, R. J. (2010). Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. *American Journal of Epidemiology*, 172(7), 843–854.

<https://doi.org/10.1093/aje/kwq198>

Stürmer, T., Schneeweiss, S., Rothman, K. J., Avorn, J., & Glynn, R. J. (2007). Performance of propensity score calibration--a simulation study. *American Journal of Epidemiology*, 165(10), 1110–1118.

<https://doi.org/10.1093/aje/kwm074>

Suchard, M. A., Zorych, I., Simpson, S. E., Schuemie, M. J., Ryan, P. B., & Madigan, D. (2013). Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. *Drug Safety*, 36 Suppl 1, S83-93.

<https://doi.org/10.1007/s40264-013-0100-4>

- Suissa, S. (1995). The case-time-control design. *Epidemiology (Cambridge, Mass.)*, 6(3), 248–253. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7619931>
- Suissa, S. (2008a). Immeasurable time bias in observational studies of drug effects on mortality. *American Journal of Epidemiology*, 168(3), 329–335. <https://doi.org/10.1093/aje/kwn135>
- Suissa, S. (2008b). Immortal Time Bias in Pharmacoepidemiology. *American Journal of Epidemiology*, 167(4), 492–499. <https://doi.org/10.1093/aje/kwm324>
- Suissa, S., & Azoulay, L. (2012). Metformin and the risk of cancer: time-related biases in observational studies. *Diabetes Care*, 35(12), 2665–2673. <https://doi.org/10.2337/dc12-0788>
- Suissa, S., Dell'aniello, S., Vahey, S., & Renoux, C. (2011). Time-window bias in case-control studies: statins and lung cancer. *Epidemiology (Cambridge, Mass.)*, 22(2), 228–231. <https://doi.org/10.1097/EDE.0b013e3182093a0f>
- Sujan, A. C., Rickert, M. E., Öberg, A. S., Quinn, P. D., Hernández-Díaz, S., Almqvist, C., D'Onofrio, B. M. (2017). Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. *JAMA*, 317(15), 1553–1562. <https://doi.org/10.1001/jama.2017.3413>
- Swanson, S. A., & Hernán, M. A. (2013). Commentary: how to report instrumental variable analyses (suggestions welcome). *Epidemiology (Cambridge, Mass.)*, 24(3), 370–374. <https://doi.org/10.1097/EDE.0b013e31828d0590>
- Swanson, S. A., Robins, J. M., Miller, M., & Hernán, M. A. (2015). Selecting on Treatment: A Pervasive Form of Bias in Instrumental Variable Analyses. *American Journal of Epidemiology*, 181(3), 191–197. <https://doi.org/10.1093/aje/kwu284>
- Tadrous, M., Gagne, J. J., Stürmer, T., & Cadarette, S. M. (2013). Disease Risk Score (DRS) as a Confounder Summary Method: Systematic Review and Recommendations. *Pharmacoepidemiology and Drug Safety*, 22(2), 122–129. <https://doi.org/10.1002/pds.3377>
- Tannen Richard L., Weiner Mark G., & Xie Dawei. (2008). Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the ‘prior event rate ratio’ to adjust for unmeasured confounding by indication. *Pharmacoepidemiology and Drug Safety*, 17(7), 671–685. <https://doi.org/10.1002/pds.1584>
- Théophile, H., Laporte, J.-R., Moore, N., Martin, K.-L., & Bégaud, B. (2011). The case-population study design: an analysis of its application in pharmacovigilance. *Drug Safety*, 34(10), 861–868. <https://doi.org/10.2165/11592140-000000000-00000>
- Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *Canadian Medical Association Journal*, 180(10), E47–E57. <https://doi.org/10.1503/cmaj.090523>
- Toh, S., García Rodríguez, L. A., & Hernán, M. A. (2011). Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. *Pharmacoepidemiology and Drug Safety*, 20(8), 849–857. <https://doi.org/10.1002/pds.2152>
- Uddin, M. J., Groenwold, R. H. H., de Boer, A., Belitser, S. V., Roes, K. C. B., Hoes, A. W., & Klungel, O. H. (2014). Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. *Pharmacoepidemiology and Drug Safety*, 23(2), 165–177. <https://doi.org/10.1002/pds.3555>
- Uddin Md. Jamal, Groenwold Rolf H. H., Boer Anthonius, Afonso Ana S. M., Primatesta Paola, Becker Claudia, ... Klungel Olaf H. (2016). Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and Drug Safety*, 25(S1), 132–141. <https://doi.org/10.1002/pds.3860>

- Uddin Md Jamal, Groenwold Rolf H. H., Staa Tjeerd P., Boer Anthonius, Belitser Svetlana V., Hoes Arno W., Klungel Olaf H. (2015). Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. *Pharmacoepidemiology and Drug Safety*, 24(5), 468–477. <https://doi.org/10.1002/pds.3724>
- Van Holle, L., & Bauchau, V. (2014). Use of logistic regression to combine two causality criteria for signal detection in vaccine spontaneous report data. *Drug Safety*, 37(12), 1047–1057. <https://doi.org/10.1007/s40264-014-0237-9>
- van Staa, T. P., Abenhaim, L., & Leufkens, H. (1994). A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. *Journal of Clinical Epidemiology*, 47(2), 183–189. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8113827>
- van Staa, T.-P., Dyson, L., McCann, G., Padmanabhan, S., Belatri, R., Goldacre, B., Smeeth, L. (2014). The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. *Health Technology Assessment (Winchester, England)*, 18(43), 1–146. <https://doi.org/10.3310/hta18430>
- Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., ... STROBE Initiative. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology (Cambridge, Mass.)*, 18(6), 805–835. <https://doi.org/10.1097/EDE.0b013e3181577511>
- VanderWeele, T. J. (2009). On the distinction between interaction and effect modification. *Epidemiology (Cambridge, Mass.)*, 20(6), 863–871. <https://doi.org/10.1097/EDE.0b013e3181ba333c>
- Wang, S., Linkletter, C., Maclure, M., Dore, D., Mor, V., Buka, S., & Wellenius, G. A. (2011). Future cases as present controls to adjust for exposure trend bias in case-only studies. *Epidemiology (Cambridge, Mass.)*, 22(4), 568–574. <https://doi.org/10.1097/EDE.0b013e31821d09cd>
- Wang, S. V., Schneeweiss, S., Maclure, M., & Gagne, J. J. (2014). “First-wave” bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. *American Journal of Epidemiology*, 180(6), 636–644. <https://doi.org/10.1093/aje/kwu162>
- Weldeselassie, Y. G., Whitaker, H. J., & Farrington, C. P. (2011). Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. *Epidemiology and Infection*, 139(12), 1805–1817. <https://doi.org/10.1017/S0950268811001531>
- Whitaker, H. J., Farrington, C. P., Spiessens, B., & Musonda, P. (2006). Tutorial in biostatistics: the self-controlled case series method. *Statistics in Medicine*, 25(10), 1768–1797. <https://doi.org/10.1002/sim.2302>
- Williamson, E., Morley, R., Lucas, A., & Carpenter, J. (2012). Propensity scores: from naive enthusiasm to intuitive understanding. *Statistical Methods in Medical Research*, 21(3), 273–293. <https://doi.org/10.1177/0962280210394483>
- Wisniewski, A. F. Z., Bate, A., Bousquet, C., Brueckner, A., Candore, G., Juhlin, K., Norén, G. N. (2016). Good Signal Detection Practices: Evidence from IMI PROTECT. *Drug Safety*, 39(6), 469–490. <https://doi.org/10.1007/s40264-016-0405-1>
- Witteman, J. C., D’Agostino, R. B., Stijnen, T., Kannel, W. B., Cobb, J. C., de Ridder, M. A., Robins, J. M. (1998). G-estimation of causal effects: isolated systolic hypertension and cardiovascular death in the Framingham Heart Study. *American Journal of Epidemiology*, 148(4), 390–401. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9717884>
- Xu, S., Zhang, L., Nelson, J. C., Zeng, C., Mullooly, J., McClure, D., & Glanz, J. (2011). Identifying optimal risk windows for self-controlled case series studies of vaccine safety. *Statistics in Medicine*, 30(7), 742–752. <https://doi.org/10.1002/sim.4125>
- Zhou, Z., Rahme, E., Abrahamowicz, M., & Pilote, L. (2005). Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. *American Journal of Epidemiology*, 162(10), 1016–1023. <https://doi.org/10.1093/aje/kwi307>

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Moher, D. (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*, 337, a2390. <https://doi.org/10.1136/bmj.a2390>

References – Chapter 6

Gail MH, Benichou J. (2000). *Encyclopedia of Epidemiologic Methods* (2000th ed.). Wiley.

ICH E9 'Statistical Principles for Clinical Trials.' (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). (n.d.). Retrieved from <http://www.ich.org/home.html>

Jones, M. P. (1996). Indicator and Stratification Methods for Missing Explanatory Variables in Multiple Linear Regression. *Journal of the American Statistical Association*, 91(433), 222–230. <https://doi.org/10.2307/2291399>

Lee, K. J., & Carlin, J. B. (2012). Recovery of information from multiple imputation: a simulation study. *Emerging Themes in Epidemiology*, 9(1), 3. <https://doi.org/10.1186/1742-7622-9-3>

Little RJA, Rubin DB. (2002). *Statistical analysis with missing data* (2nd ed.). Wiley.

Moons, K. G. M., Donders, R. A. R. T., Stijnen, T., & Harrell, F. E. (2006). Using the outcome for imputation of missing predictor values was preferred. *Journal of Clinical Epidemiology*, 59(10), 1092–1101. <https://doi.org/10.1016/j.jclinepi.2006.01.009>

Rosenbaum PR. (2010). *Design of Observational Studies*. Springer.

Rothman K, Greenland S, Lash T. (2008). *Modern Epidemiology* (3rd ed.). Lippincott Williams & Wilkins.

Rubin DB. (1987). *Multiple Imputation for Nonresponse in Surveys*. Wiley.

Schafer JL. (1997). *Analysis of Incomplete Multivariate Data*. Chapman & Hall.

Welch, C. A., Petersen, I., Bartlett, J. W., White, I. R., Marston, L., Morris, R. W., Carpenter, J. (2014). Evaluation of two-fold fully conditional specification multiple imputation for longitudinal electronic health record data. *Statistics in Medicine*, 33(21), 3725–3737. <https://doi.org/10.1002/sim.6184>

References – Chapter 7

Bate, A., Reynolds, R. F., & Caubel, P. (2018). The hope, hype and reality of Big Data for pharmacovigilance. *Therapeutic Advances in Drug Safety*, 9(1), 5–11. <https://doi.org/10.1177/2042098617736422>

Blomgren, K. J., Sundström, A., Steineck, G., & Wilholm, B.-E. (2006). Interviewer variability - quality aspects in a case-control study. *European Journal of Epidemiology*, 21(4), 267–277. <https://doi.org/10.1007/s10654-006-0017-7>

Commission Implementing Regulation (EU) No 520/2012. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

EuroDURG. (n.d.). Retrieved from <https://www.pharmacoepi.org/eurodurg/>

European Forum for Good Clinical Practice (EFGCP) Guidelines. (n.d.). Retrieved April 6, 2018, from <http://www.efgcp.eu/Publications.asp?Type=EFGCP%20publications&L1=13&L2=1>

FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

- Furu, K. (2008). Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. *Norsk Epidemiologi*, 18(2). <https://doi.org/10.5324/nje.v18i2.23>
- German Society for Epidemiology (DGEpi). Good Practice in Secondary Data Analysis Version 2. (n.d.). Retrieved from http://dgepi.de/fileadmin/pdf/leitlinien/gps-version2-final_ENG.pdf
- Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010). Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *British Journal of Clinical Pharmacology*, 69(1), 4–14. <https://doi.org/10.1111/j.1365-2125.2009.03537.x>
- Hoven, J. L., Haaijer-Ruskamp, F. M., Vander Stichele, R. H., & DURQUIM Scientific Committee. (2005). Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004). *European Journal of Clinical Pharmacology*, 60(11), 831–834. <https://doi.org/10.1007/s00228-004-0845-x>
- ICH Guideline for Good Clinical Practice E6(R1). (n.d.). Retrieved from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf
- ICH Guideline for Good Clinical Practice E6(R2). (n.d.). Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2_Step_4_2016_1109.pdf
- Imperial College Academic Health Science Centre (AHSC)'s Quality Control and Quality Assurance SOP. (n.d.). Retrieved from http://www.imperial.ac.uk/media/imperial-college/research-and-innovation/joint-research-compliance-office/public/JRCO_SOP_025_QAQC_V7.0_25Oct2017.pdf
- International Standards Organization, ISO 9000 Quality management systems. (n.d.). Retrieved April 6, 2018, from <https://www.iso.org/standard/45481.html>
- ISO Quality management principles. (n.d.). Retrieved from <http://www.iso.org/iso/pub100080.pdf>
- ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>
- Knatterud, G. L., Rockhold, F. W., George, S. L., Barton, F. B., Davis, C. E., Fairweather, W. R., O'Neill, R. (1998). Guidelines for Quality Assurance in Multicenter Trials: A Position Paper. *Controlled Clinical Trials*, 19(5), 477–493. [https://doi.org/10.1016/S0197-2456\(98\)00033-6](https://doi.org/10.1016/S0197-2456(98)00033-6)
- Lindquist, M. (2004). Data quality management in pharmacovigilance. *Drug Safety*, 27(12), 857–870. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/15366974>
- McGraw, M. J., George, A. N., Shearn, S. P., Jr, T. F. H., & Hall, R. L. (2010). Principles of Good Clinical Practice. Pharmaceutical Press.
- Prathibha Varkey. (2010). Medical Quality Management: Theory and Practice. Jones and Bartlett Publishers International. Retrieved from <http://www.jblearning.com/catalog/9780763760342/>
- Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition. (n.d.). Retrieved August 3, 2018, from <https://effectivehealthcare.ahrq.gov/topics/registries-guide-3rd-edition-addendum/overview>
- Reisch, L. M., Fosse, J. S., Beverly, K., Yu, O., Barlow, W. E., Harris, E. L., Elmore, J. G. (2003). Training, quality assurance, and assessment of medical record abstraction in a multisite study. *American Journal of Epidemiology*, 157(6), 546–551. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12631545>
- Reppe, L. A., Spigset, O., Kampmann, J. P., Damkier, P., Christensen, H. R., Böttiger, Y., & Schjøtt, J. (2017). Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres. *European Journal of Clinical Pharmacology*, 73(5), 623–631. <https://doi.org/10.1007/s00228-017-2209-3>
- Sprenger, K., Nickerson, D., Meeker-O'Connell, A., & Morrison, B. W. (2013). Quality by Design in Clinical Trials: A Collaborative Pilot With FDA. *Therapeutic Innovation & Regulatory Science*, 47(2), 161–166. <https://doi.org/10.1177/0092861512458909>

Theobald, K., Capan, M., Herbold, M., Schinzel, S., & Hundt, F. (2009). Quality assurance in non-interventional studies. *GMS German Medical Science*, 7. <https://doi.org/10.3205/000088>

Wang V.C.X. (2017). *Encyclopedia of Strategic Leadership and Management- Quantitative Data Analysis for Quality Control in Strategic Management*. Wiley.

Whitney, C. W., Lind, B. K., & Wahl, P. W. (1998). Quality assurance and quality control in longitudinal studies. *Epidemiologic Reviews*, 20(1), 71–80. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9762510>

References – Chapter 8

Cohen, J. F., Korevaar, D. A., Altman, D. G., Bruns, D. E., Gatsonis, C. A., Hooft, L., ... Bossuyt, P. M. M. (2016). STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. *BMJ Open*, 6(11), e012799. <https://doi.org/10.1136/bmjopen-2016-012799>

Declaration of Helsinki. (n.d.). Retrieved April 6, 2018, from <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

ENCePP Checklist for Study Protocols. (n.d.). Retrieved from http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml

ENCePP Code of Conduct. (n.d.). Retrieved from http://www.encepp.eu/code_of_conduct/index.shtml

Enhancing the QUality and Transparency Of Health Research (EQUATOR) - Library for health research reporting. (n.d.). Retrieved April 6, 2018, from <http://www.equator-network.org/>

European Union electronic Register of Post-Authorisation Studies (EU PAS Register). (n.d.). Retrieved April 5, 2018, from http://www.encepp.eu/encepp_studies/indexRegister.shtml

FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets. (n.d.). Retrieved from <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

Good ReseArch for Comparative Effectiveness (GRACE) guidance. (n.d.). Retrieved from <https://www.graceprinciples.org/>

Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies (PASS). (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2013/01/WC500137939.pdf

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies. (n.d.). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/10/WC500133174.pdf

Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WCOB01ac058058f32c

ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. (n.d.). Retrieved April 6, 2018, from <http://www.icmje.org/recommendations/>

IEA Good Epidemiological Practice (GEP). (n.d.). Retrieved June 28, 2018, from <http://ieaweb.org/good-epidemiological-practice-gep/>

International Committee of Medical Journal Editors (ICMJE). (n.d.). Retrieved June 28, 2018, from <http://www.icmje.org/>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Kelly, W. N., Arellano, F. M., Barnes, J., Bergman, U., Edwards, I. R., Fernandez, A. M., ... International Society of Pharmacovigilance. (2007). Guidelines for submitting adverse event reports for publication. *Pharmacoepidemiology and Drug Safety*, 16(5), 581–587. <https://doi.org/10.1002/pds.1399>

Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. *Quality of Reporting of Meta-analyses*. *Lancet* (London, England), 354(9193), 1896–1900. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10584742>

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*, 339, b2535. <https://doi.org/10.1136/bmj.b2535>

PRISMA statement. (n.d.). Retrieved April 6, 2018, from <http://www.prisma-statement.org/>

Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*, 340, c332. <https://doi.org/10.1136/bmj.c332>

Simera, I., Moher, D., Hoey, J., Schulz, K. F., & Altman, D. G. (2010). A catalogue of reporting guidelines for health research. *European Journal of Clinical Investigation*, 40(1), 35–53. <https://doi.org/10.1111/j.1365-2362.2009.02234.x>

STROBE Statement. (n.d.). Retrieved April 6, 2018, from <https://www.strobe-statement.org/index.php?id=strobe-home>

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., (2000). Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. *JAMA*, 283(15), 2008–2012. <https://doi.org/10.1001/jama.283.15.2008>

The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines. (n.d.). Retrieved April 6, 2018, from <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125620>

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. (n.d.). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Retrieved April 6, 2018, from <https://strobe-statement.org/index.php?id=strobe-publications>

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. (2017). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Pharmacoepidemiology and Drug Safety*, 26(9), 1018–1032. <https://doi.org/10.1002/pds.4295>

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Moher, D. (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*, 337, a2390. <https://doi.org/10.1136/bmj.a2390>

References – Chapter 9

Agency for Healthcare Research and Quality (AHRQ). (n.d.). Retrieved April 5, 2018, from <https://www.ahrq.gov/>

Agency for Healthcare Research and Quality (AHRQ). Registries for Evaluating Patient Outcomes: A User’s Guide 3rd Edition. (n.d.). Retrieved April 5, 2018, from <https://www.effectivehealthcare.ahrq.gov/topics/registries-guide-3rd-edition/research/>

CIOMS. International Ethical Guidelines for Epidemiological Studies. (n.d.). Retrieved April 9, 2018, from <https://cioms.ch/shop/product/international-ethical-guidelines-for-epidemiological-studies/>

CIOMS International Ethical Guidelines for Health-related Research Involving Humans. (n.d.). Retrieved from <https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf>

Commission Implementing Regulation (EU) No 520/2012. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Declaration of Helsinki. (n.d.). Retrieved April 6, 2018, from <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995. (n.d.). Retrieved from <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:31995L0046&from=en>

Directive 2001/20/EC of the European Parliament and of the Council. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF>

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF>

Directive 2005/28/EC Guidelines for Good Clinical Practice. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:091:0013:0019:en:PDF>

ENCePP Code of Conduct. (n.d.). Retrieved April 9, 2018, from http://www.encepp.eu/code_of_conduct/

EU Charter of Fundamental Rights. (n.d.). Retrieved from https://ec.europa.eu/info/aid-development-cooperation-fundamental-rights/your-rights-eu/eu-charter-fundamental-rights_en

European Union electronic Register of Post-Authorisation Studies (EU PAS Register). (n.d.). Retrieved April 5, 2018, from http://www.encepp.eu/encepp_studies/indexRegister.shtml

Guideline on good pharmacovigilance practices (GVP) - Module VIII – Post-authorisation safety studies. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=Wc0b01ac058058f32c

Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products. (n.d.). Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=Wc0b01ac058058f32c

ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. (n.d.). Retrieved April 6, 2018, from <http://www.icmje.org/recommendations/>

IEA Good Epidemiology Practice Guideline (GEP). (n.d.). Retrieved from <http://ieaweb.org/good-epidemiological-practice-gep/>

International Committee of Medical Journal Editors (ICMJE). (n.d.). Retrieved April 9, 2018, from <http://www.icmje.org/>

International Epidemiological Association (IEA). (n.d.). Retrieved April 9, 2018, from <http://ieaweb.org/>

International Society for Pharmacoepidemiology (ISPE). (n.d.). Retrieved April 9, 2018, from <https://www.pharmacoepi.org/>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (n.d.). Retrieved from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

ISPE Guidelines on Data Privacy, Medical Record Confidentiality, and Research in the Interest of Public Health. (n.d.). Retrieved April 9, 2018, from <https://www.pharmacoepi.org/resources/policies/privacy/>

Kurz, X., Bauchau, V., Mahy, P., Glismann, S., van der Aa, L. M., Simondon, F., & ADVANCE consortium. (2017). The ADVANCE Code of Conduct for collaborative vaccine studies. *Vaccine*, 35(15), 1844–1855.
<https://doi.org/10.1016/j.vaccine.2017.02.039>

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the protection of individuals with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC. (n.d.). Retrieved from <https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1511278760489&uri=CELEX:52017PC0008>

Regulation (EC) No. 45/2001 of the European Parliament and of the Council of 18 December 2000. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:008:0001:0022:EN:PDF>

Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016. (n.d.). Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.119.01.0001.01.ENG&toc=OJ:L:2016:119:TOC

Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. (n.d.). Retrieved from <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&rid=1>

Regulation (EU) No. 1235/2010 of the European Parliament and of the Council of 15 December 2010. (n.d.). Retrieved from <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF>

References – Chapter 10.1.

Agency for Healthcare Research and Quality (AHRQ). (n.d.). Retrieved April 5, 2018, from <https://www.ahrq.gov/>

AHRQ Comparative Effectiveness Reviews. (2005). Agency for Healthcare Research and Quality (US).

AHRQ. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. (n.d.). Retrieved from <https://www.effectivehealthcare.ahrq.gov/topics/observational-cer-protocol/research>

AHRQ. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. (n.d.). Retrieved from <https://effectivehealthcare.ahrq.gov/topics/cer-methods-guide/overview>

AHRQ. Summary Variables in Observational Research: Propensity Scores and Disease Risk Scores. Effective Health Care Program Research Report No. 33. May 2012. (n.d.). Retrieved from <https://effectivehealthcare.ahrq.gov/topics/observational-research-scores/research>

AHRQ. The Incident User Design in Comparative Effectiveness Research. Effective Health Care Program Research Report No. 33. May 2012. (n.d.). Retrieved from <https://effectivehealthcare.ahrq.gov/topics/incident-user-design/research>

Avorn J. (2007). In defense of Pharmacoepidemiology-Embracing the Yin and Yang of Drug Research. *N Engl J Med*, 357(22), 2219–2221. Retrieved from <http://www.nejm.org/doi/pdf/10.1056/NEJMp0706892>

Black, N. (1996). Why we need observational studies to evaluate the effectiveness of health care. *BMJ (Clinical Research Ed.)*, 312(7040), 1215–1218. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8634569>

Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User Survey. (n.d.). Retrieved April 9, 2018, from <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146444>

COMET - Core Outcome Measures in Effectiveness Trials Initiative. (n.d.). Retrieved April 9, 2018, from <http://www.comet-initiative.org/>

Crystal, S., Gaboda, D., Lucas, J., Gerhard, T., & Chakravarty, S. (2010). Assessing medication exposures and outcomes in the frail elderly: assessing research challenges in nursing home pharmacotherapy. *Medical Care*, 48(6 Suppl), S23-31. <https://doi.org/10.1097/MLR.0b013e3181de9d10>

DARTNet Institute. (n.d.). Retrieved April 9, 2018, from <http://www.dartnet.info/>

EUnethTA. Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals. (n.d.). Retrieved April 9, 2018, from <https://www.eunethta.eu/the-final-version-of-hta-core-model-and-the-methodological-guidelines-for-rapid-rea-of-pharmaceuticals-is-now-available/>

European Network for Health Technology Assessment (EUnethTA). (n.d.). Retrieved June 28, 2018, from <https://www.eunethta.eu/>

GRACE Principles - Good ReseArch for Comparative Effectiveness. (n.d.). Retrieved April 9, 2018, from <https://www.graceprinciples.org/>

GRADE Working Group. (n.d.). Retrieved June 28, 2018, from <http://www.gradeworkinggroup.org/>

GRADE working group. 6-part 2008 BMJ series. (n.d.). Retrieved from <http://www.cochrane.de/grade-publications#bmj>

GRADE working group. Journal of Clinical Epidemiology series of articles. (n.d.). Retrieved from <https://www.jclinepi.com/content/jce-GRADE-Series>

Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group. (n.d.). Retrieved April 9, 2018, from <http://www.gradeworkinggroup.org/>

Harker, J., & Kleijnen, J. (2012). What is a rapid review? A methodological exploration of rapid reviews in Health Technology Assessments. *International Journal of Evidence-Based Healthcare*, 10(4), 397–410. <https://doi.org/10.1111/j.1744-1609.2012.00290.x>

Hernán, M. A., & Robins, J. M. (2016). Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *American Journal of Epidemiology*, 183(8), 758–764. <https://doi.org/10.1093/aje/kwv254>

IMI GetReal. (n.d.). Retrieved June 28, 2018, from <http://www.imi-getreal.eu/>

International Society for Pharmacoeconomics and Outcome Research (ISPOR). (n.d.). Retrieved April 5, 2018, from <https://www.ispor.org/>

ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. (n.d.). Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartI.pdf>

ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. (n.d.). Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartII.pdf>

ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. (n.d.). Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartIII.pdf>

Johnson, E. S., Bartman, B. A., Briesacher, B. A., Fleming, N. S., Gerhard, T., Kornegay, C. J., ... Schneeweiss, S. (2013). The incident user design in comparative effectiveness research. *Pharmacoepidemiology and Drug Safety*, 22(1), 1–6. <https://doi.org/10.1002/pds.3334>

Klungel, O. H., Martens, E. P., Psaty, B. M., Grobbee, D. E., Sullivan, S. D., Stricker, B. H. C., ... de Boer, A. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. *Journal of Clinical Epidemiology*, 57(12), 1223–1231. <https://doi.org/10.1016/j.jclinepi.2004.03.011>

Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015). The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ*, 350, h2147. <https://doi.org/10.1136/bmj.h2147>

Patient-Centered Outcome Research Institute (PCORI). (n.d.). Retrieved April 9, 2018, from <https://www.pcori.org/>

- PCORI. Methodology Report. (2014, July 30). Retrieved April 9, 2018, from <https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-methodology-report>
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs | NEJM. (n.d.). Retrieved April 9, 2018, from <http://www.nejm.org/doi/full/10.1056/NEJM200006223422507#t=article>
- Ray, W. A. (2003). Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. *American Journal of Epidemiology*, 158(9), 915–920. <https://doi.org/10.1093/aje/kwg231>
- Real World Evidence Navigator. (n.d.). Retrieved April 9, 2018, from <https://rwe-navigator.eu/>
- S, S. (2007). Developments in Post-marketing Comparative Effectiveness Research. *Clinical Pharmacology and Therapeutics*, 82(2), 143–156. <https://doi.org/10.1038/sj.clpt.6100249>
- Sauer, B. C., Brookhart, A., Roy, J., & Vanderweele, T. (2013). A Review of Covariate Selection for Nonexperimental Comparative Effectiveness Research. *Pharmacoepidemiology and Drug Safety*, 22(11), 1139–1145. <https://doi.org/10.1002/pds.3506>
- Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*, 58(4), 323–337. <https://doi.org/10.1016/j.jclinepi.2004.10.012>
- Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H and Brookhart MA. (2009). High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology*, 20(4), 512–522. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077219/pdf/nihms282669.pdf>
- Schwartz, D., & Lellouch, J. (2009). Explanatory and pragmatic attitudes in therapeutical trials. *Journal of Clinical Epidemiology*, 62(5), 499–505. <https://doi.org/10.1016/j.jclinepi.2009.01.012>
- Selby, J. V., Forsythe, L., & Sox, H. C. (2015). Stakeholder-Driven Comparative Effectiveness Research: An Update From PCORI. *JAMA*, 314(21), 2235–2236. <https://doi.org/10.1001/jama.2015.15139>
- Sox, H. C., & Goodman, S. N. (2012). The methods of comparative effectiveness research. *Annual Review of Public Health*, 33, 425–445. <https://doi.org/10.1146/annurev-publhealth-031811-124610>
- Staa, T.-P. van, Goldacre, B., Gulliford, M., Cassell, J., Pirmohamed, M., Taweel, A., ... Smeeth, L. (2012). Pragmatic randomised trials using routine electronic health records: putting them to the test. *BMJ*, 344, e55. <https://doi.org/10.1136/bmj.e55>
- Tadrous, M., Gagne, J. J., Stürmer, T., & Cadarette, S. M. (2013). Disease Risk Score (DRS) as a Confounder Summary Method: Systematic Review and Recommendations. *Pharmacoepidemiology and Drug Safety*, 22(2), 122–129. <https://doi.org/10.1002/pds.3377>
- Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *Canadian Medical Association Journal*, 180(10), E47–E57. <https://doi.org/10.1503/cmaj.090523>
- Toh, S., Gagne, J. J., Rassen, J. A., Fireman, B. H., Kulldorff, M., & Brown, J. S. (2013). Confounding adjustment in comparative effectiveness research conducted within distributed research networks. *Medical Care*, 51(8 Suppl 3), S4–10. <https://doi.org/10.1097/MLR.0b013e31829b1bb1>
- US National Library of Medicine: Queries on CER. (n.d.). [Other]. Retrieved April 9, 2018, from <https://www.nlm.nih.gov/hsrinfo/cer.html>
- Valuck, R. J., Anderson, H. O., Libby, A. M., Brandt, E., Bryan, C., Allen, R. R., ... Pace, W. D. (2012). Enhancing electronic health record measurement of depression severity and suicide ideation: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. *Journal of the American Board of Family Medicine: JABFM*, 25(5), 582–593. <https://doi.org/10.3122/jabfm.2012.05.110053>

When are observational studies as credible as randomised trials? - The Lancet. (n.d.). Retrieved April 9, 2018, from [http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(04\)16261-2.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(04)16261-2.pdf)

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., ... Moher, D. (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*, 337, a2390. <https://doi.org/10.1136/bmj.a2390>

References – Chapter 10.2.

ADVANCE Report on appraisal of vaccine safety methods. (n.d.). Retrieved from http://www.advance-vaccines.eu/app/archivos/publicacion/67/ADVANCE_D4%20appraisal%20safety%20methods_final_PU.pdf

Andrews, N. (2012). Epidemiological designs for vaccine safety assessment: methods and pitfalls. *Biologicals: Journal of the International Association of Biological Standardization*, 40(5), 389–392. <https://doi.org/10.1016/j.biologicals.2011.08.010>

Banks, D., Woo, E. J., Burwen, D. R., Perucci, P., Braun, M. M., & Ball, R. (2005). Comparing data mining methods on the VAERS database. *Pharmacoepidemiology and Drug Safety*, 14(9), 601–609. <https://doi.org/10.1002/pds.1107>

Beck, C. R., McKenzie, B. C., Hashim, A. B., Harris, R. C., University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, & Nguyen-Van-Tam, J. S. (2012). Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. *The Journal of Infectious Diseases*, 206(8), 1250–1259. <https://doi.org/10.1093/infdis/jis487>

Black, S., Eskola, J., Siegrist, C.-A., Halsey, N., Macdonald, N., Law, B., Vellozzi, C. (2009). Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. *Lancet (London, England)*, 374(9707), 2115–2122. [https://doi.org/10.1016/S0140-6736\(09\)61877-8](https://doi.org/10.1016/S0140-6736(09)61877-8)

Brighton Collaboration. (n.d.). Retrieved April 9, 2018, from <https://www.brightoncollaboration.org/>

Broome, C. V., Facklam, R. R., & Fraser, D. W. (1980). Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. *The New England Journal of Medicine*, 303(10), 549–552. <https://doi.org/10.1056/NEJM198009043031003>

Brown, J. S., Kulldorff, M., Chan, K. A., Davis, R. L., Graham, D., Pettus, P. T., ... Platt, R. (2007). Early detection of adverse drug events within population-based health networks: application of sequential testing methods. *Pharmacoepidemiology and Drug Safety*, 16(12), 1275–1284. <https://doi.org/10.1002/pds.1509>

Carvajal, A., Ortega, P. G., Sáinz, M., Velasco, V., Salado, I., Arias, L. H. M., ... Castrodeza, J. (2011). Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting. *Vaccine*, 29(3), 519–522. <https://doi.org/10.1016/j.vaccine.2010.10.067>

Castilla, J., Beristain, X., Martínez-Artola, V., Navascués, A., García Cenoz, M., Alvarez, N., ... Barricarte, A. (2012). Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. *Vaccine*, 30(3), 539–543. <https://doi.org/10.1016/j.vaccine.2011.11.071>

Charlton R, De Vries C. (n.d.). Systematic overview of data sources for Drug Safety in pregnancy research. Retrieved from http://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf

CIOMS Guide to Vaccine Safety Communication. (n.d.). Retrieved June 29, 2018, from <https://cioms.ch/shop/product/cioms-guide-vaccine-safety-communication/>

CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Definition and Application of Terms for Vaccine Pharmacovigilance. Council for International Organizations of Medical Sciences (CIOMS), Geneva 2012. (n.d.). Retrieved from http://www.who.int/vaccine_safety/initiative/tools/CIOMS_report_WG_vaccine.pdf

- de Bie, S., Verhamme, K. M. C., Straus, S. M. J. M., Stricker, B. H. C., & Sturkenboom, M. C. J. M. (2012). Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection. *Drug Safety*, 35(4), 335–346. <https://doi.org/10.2165/11598120-000000000-00000>
- De Serres, G., Pilishvili, T., Link-Gelles, R., Reingold, A., Gershman, K., Petit, S., Moore, M. (2012). Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. *Vaccine*, 30(27), 4067–4072. <https://doi.org/10.1016/j.vaccine.2012.04.017>
- De Smedt, T., Merrall, E., Macina, D., Perez-Vilar, S., Andrews, N., & Bollaerts, K. (2018). Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness. *PloS One*, 13(6), e0199180. <https://doi.org/10.1371/journal.pone.0199180>
- De Vito, C., Manzoli, L., Marzuillo, C., Anastasi, D., Boccia, A., & Villari, P. (2007). A systematic review evaluating the potential for bias and the methodological quality of meta-analyses in vaccinology. *Vaccine*, 25(52), 8794–8806. <https://doi.org/10.1016/j.vaccine.2007.10.034>
- Dennis, J., Hawken, S., Krewski, D., Birkett, N., Gheorghe, M., Frei, J., Little, J. (2011). Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. *International Journal of Epidemiology*, 40(5), 1329–1341. <https://doi.org/10.1093/ije/dyr088>
- Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., & Sturkenboom, M. (2011). Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. *BMJ*, 343, d3908. <https://doi.org/10.1136/bmj.d3908>
- Dudareva-Vizule, S., Koch, J., An der Heiden, M., Oberle, D., Keller-Stanislawski, B., & Wichmann, O. (2012). Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. *Human Vaccines & Immunotherapeutics*, 8(10), 1407–1415. <https://doi.org/10.4161/hv.21593>
- ECDC. Effectiveness of rotavirus vaccination – Generic study protocol for retrospective case control studies based on computerised databases. (n.d.). Retrieved from <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/rotavirus-vaccination-case-control-april2013.pdf>
- ECDC. Effectiveness of rotavirus vaccination – Generic study protocol for retrospective cohort studies based on computerised databases. (n.d.). Retrieved from <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/rotavirus-vaccination-cohort-study-april2013.pdf>
- ECDC: European Centre for Disease Prevention and Control. (n.d.). Retrieved July 2, 2018, from <http://ecdc.europa.eu/en/home>
- ECDC. Impact of rotavirus vaccination - Generic Study Protocol. (n.d.). Retrieved from <https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Rotavirus-impact-vaccination-April-2013.pdf>
- Effects of vaccines in patients with sickle cell disease: a systematic review protocol. (n.d.). Retrieved July 2, 2018, from <https://bmjopen.bmj.com/content/8/3/e021140.long>
- Escolano, S., Hill, C., & Tubert-Bitter, P. (2013). A new self-controlled case series method for analyzing spontaneous reports of adverse events after vaccination. *American Journal of Epidemiology*, 178(9), 1496–1504. <https://doi.org/10.1093/aje/kwt128>
- Evans, S. J. W. (2008). Stratification for spontaneous report databases. *Drug Safety*, 31(11), 1049–1052. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18840024>
- Farrington, C. P. (2004). Control without separate controls: evaluation of vaccine safety using case-only methods. *Vaccine*, 22(15–16), 2064–2070. <https://doi.org/10.1016/j.vaccine.2004.01.017>

- Farrington, C. P., Firth, M. J., Moulton, L. H., Ravn, H., Andersen, P. K., Evans, S., & Working Group on Non-specific Effects of Vaccines. (2009). Epidemiological studies of the non-specific effects of vaccines: II--methodological issues in the design and analysis of cohort studies. *Tropical Medicine & International Health: TM & IH*, 14(9), 977–985. <https://doi.org/10.1111/j.1365-3156.2009.02302.x>
- Fine, P. E. M., Williams, T. N., Aaby, P., Källander, K., Moulton, L. H., Flanagan, K. L., Working Group on Non-specific Effects of Vaccines. (2009). Epidemiological studies of the “non-specific effects” of vaccines: I--data collection in observational studies. *Tropical Medicine & International Health: TM & IH*, 14(9), 969–976. <https://doi.org/10.1111/j.1365-3156.2009.02301.x>
- Glanz, J. M., McClure, D. L., Xu, S., Hambidge, S. J., Lee, M., Kolczak, M. S., France, E. K. (2006). Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. *Journal of Clinical Epidemiology*, 59(8), 808–818. <https://doi.org/10.1016/j.jclinepi.2005.11.012>
- Global Alignment of Immunization Safety Assessment in pregnancy (GAIA). (n.d.). Retrieved July 2, 2018, from <http://gaia-consortium.net/>
- Greene, S. K., Kullendorff, M., Lewis, E. M., Li, R., Yin, R., Weintraub, E. S., Lee, G. M. (2010). Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. *American Journal of Epidemiology*, 171(2), 177–188. <https://doi.org/10.1093/aje/kwp345>
- Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations I: Vaccines for prophylaxis against infectious diseases. (n.d.). Retrieved June 29, 2018, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c#section3
- Halloran, M. E., Haber, M., Longini, I. M., & Struchiner, C. J. (1991). Direct and Indirect Effects in Vaccine Efficacy and Effectiveness. *American Journal of Epidemiology*, 133(4), 323–331. <https://doi.org/10.1093/oxfordjournals.aje.a115884>
- Hanquet, G., Valenciano, M., Simondon, F., & Moren, A. (2013). Vaccine effects and impact of vaccination programmes in post-licensure studies. *Vaccine*, 31(48), 5634–5642. <https://doi.org/10.1016/j.vaccine.2013.07.006>
- Harmonising Immunisation Safety Assessment in Pregnancy. (n.d.). Retrieved July 2, 2018, from <http://gaia-consortium.net/outputs/>
- Heffernan, J. M., & Keeling, M. J. (2009). Implications of vaccination and waning immunity. *Proceedings of the Royal Society B: Biological Sciences*, 276(1664), 2071–2080. <https://doi.org/10.1098/rspb.2009.0057>
- Heininger, U., Holm, K., Caplanusi, I., Bailey, S. R., & CIOMS Working Group on Vaccine Safety. (2017). Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety - executive summary. *Vaccine*, 35(32), 3917–3921. <https://doi.org/10.1016/j.vaccine.2017.06.033>
- Hennessy, S., Liu, Z., Tsai, T. F., Strom, B. L., Wan, C. M., Liu, H. L., Halstead, S. B. (1996). Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. *Lancet (London, England)*, 347(9015), 1583–1586. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8667866>
- Hocine, M. N., Farrington, C. P., Touzé, E., Whitaker, H. J., Fourrier, A., Moreau, T., & Tubert-Bitter, P. (2007). Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. *Vaccine*, 25(31), 5938–5943. <https://doi.org/10.1016/j.vaccine.2007.05.032>
- Intussusception after Rotavirus Vaccination — Spontaneous Reports | NEJM. (n.d.). Retrieved April 9, 2018, from <http://www.nejm.org/doi/full/10.1056/NEJMc1107771>
- Jackson, M. L., & Nelson, J. C. (2013). The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*, 31(17), 2165–2168. <https://doi.org/10.1016/j.vaccine.2013.02.053>

- Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V. (2005). Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. *Lancet* (London, England), 366(9492), 1165–1174. [https://doi.org/10.1016/S0140-6736\(05\)67339-4](https://doi.org/10.1016/S0140-6736(05)67339-4)
- Klein, N. P. (2011). Vaccine safety in special populations. *Human Vaccines*, 7(2), 269–271. <https://doi.org/10.4161/hv.7.2.13860>
- Kurz, X., Domergue, F., Slattery, J., Segec, A., Szmigiel, A., & Hidalgo-Simon, A. (2011). Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. *Vaccine*, 29(26), 4378–4387. <https://doi.org/10.1016/j.vaccine.2011.04.005>
- Leino, T., Ollgren, J., Salo, H., Tiihonen, P., & Kilpi, T. (2012). First year experience of rotavirus immunisation programme in Finland. *Vaccine*, 31(1), 176–182. <https://doi.org/10.1016/j.vaccine.2012.10.068>
- Leite, A., Andrews, N. J., & Thomas, S. L. (n.d.). Near real-time vaccine safety surveillance using electronic health records—a systematic review of the application of statistical methods. *Pharmacoepidemiology and Drug Safety*, 25(3), 225–237. <https://doi.org/10.1002/pds.3966>
- Mahaux, O., Bauchau, V., & Holle, L. V. (n.d.). Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. *Pharmacoepidemiology and Drug Safety*, 25(2), 215–222. <https://doi.org/10.1002/pds.3918>
- Martin Arias, L. H., Sanz, R., Sáinz, M., Treceño, C., & Carvajal, A. (2015). Guillain-Barré syndrome and influenza vaccines: A meta-analysis. *Vaccine*, 33(31), 3773–3778. <https://doi.org/10.1016/j.vaccine.2015.05.013>
- McClure, D. L., Glanz, J. M., Xu, S., Hambidge, S. J., Mullooly, J. P., & Baggs, J. (2008). Comparison of epidemiologic methods for active surveillance of vaccine safety. *Vaccine*, 26(26), 3341–3345. <https://doi.org/10.1016/j.vaccine.2008.03.074>
- Miller, E., Andrews, N., Stellitano, L., Stowe, J., Winstone, A. M., Shneerson, J., & Verity, C. (2013). Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. *BMJ* (Clinical Research Ed.), 346, f794. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23444425>
- Nelson, J. C., Cook, A. J., Yu, O., Dominguez, C., Zhao, S., Greene, S. K., Jackson, L. A. (2012). Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. *Pharmacoepidemiology and Drug Safety*, 21 Suppl 1, 62–71. <https://doi.org/10.1002/pds.2324>
- Polyzos, K. A., Konstantelias, A. A., Pitsa, C. E., & Falagas, M. E. (2015). Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. *Obstetrics and Gynecology*, 126(5), 1075–1084. <https://doi.org/10.1097/AOG.0000000000001068>
- Pritchard, J. K., Stephens, M., Rosenberg, N. A., & Donnelly, P. (2000). Association Mapping in Structured Populations. *American Journal of Human Genetics*, 67(1), 170–181. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287075/>
- Renschmidt, C., Rieck, T., Bödeker, B., & Wichmann, O. (2015). Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany. *BMC Infectious Diseases*, 15. <https://doi.org/10.1186/s12879-015-0882-3>
- Rondy, M., Launay, O., Puig-Barberà, J., Gefenaite, G., Castilla, J., de Gaetano Donati, K., Moren, A. (2015). 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. *Euro Surveillanc*: Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 20(2). Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25613779>
- Salmon, D. A., Proschan, M., Forshee, R., Gargiullo, P., Bleser, W., Burwen, D. R., H1N1 GBS Meta-Analysis Working Group. (2013). Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. *Lancet* (London, England), 381(9876), 1461–1468. [https://doi.org/10.1016/S0140-6736\(12\)62189-8](https://doi.org/10.1016/S0140-6736(12)62189-8)

- Siegrist, C.-A., Lewis, E. M., Eskola, J., Evans, S. J. W., & Black, S. B. (2007). Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. *The Pediatric Infectious Disease Journal*, 26(11), 979–984. <https://doi.org/10.1097/INF.0b013e318149dfea>
- Simpson, C. R., Lone, N. I., Kavanagh, K., Ritchie, L. D., Robertson, C., Sheikh, A., & McMenamin, J. (2015). Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory-confirmed influenza in a Scottish population 2000 to 2009. *Euro Surveillance: Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, 20(8). Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25742433>
- Tokars, J. I., Lewis, P., DeStefano, F., Wise, M., Viray, M., Morgan, O., Vellozzi, C. (2012). The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. *Pharmacoepidemiology and Drug Safety*, 21(5), 546–552. <https://doi.org/10.1002/pds.3220>
- Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales. (n.d.). Retrieved April 9, 2018, from <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0028435>
- Vaccine Effectiveness Simulation. (n.d.). Retrieved July 2, 2018, from <http://apps.p-95.com/VEMisclassification/>
- Vaccine Safety Datalink (VSD). (2018, March 2). Retrieved April 9, 2018, from <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>
- Van Ganse, E., Letrillart, L., Borne, H., Morand, F., Robain, M., & Siegrist, C. A. (2012). Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program. *Pharmacoepidemiology and Drug Safety*, 21(3), 261–268. <https://doi.org/10.1002/pds.2243>
- Van Holle, L., & Bauchau, V. (2013). Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization. *Pharmacoepidemiology and Drug Safety*, 22(5), 477–487. <https://doi.org/10.1002/pds.3392>
- Wacholder, S., Chen, B. E., Wilcox, A., Macones, G., Gonzalez, P., Befano, B., ... CVT group. (2010). Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. *BMJ (Clinical Research Ed.)*, 340, c712. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/20197322>
- WHO Vaccine Safety Basics e-learning course. (n.d.). Retrieved April 9, 2018, from <http://vaccine-safety-training.org/home.html>
- WHO Vaccine Safety Basics. Module 4 (Surveillance). (n.d.). Retrieved April 9, 2018, from <http://vaccine-safety-training.org/overview-and-outcomes-4.html>
- Woo, E. J., Ball, R., Burwen, D. R., & Braun, M. M. (2008). Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). *Drug Safety*, 31(8), 667–674. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18636785>
- Xu, R., Luo, Y., & Chambers, C. (2012). Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. *Pharmacoepidemiology and Drug Safety*, 21(8), 844–850. <https://doi.org/10.1002/pds.3301>
- Yih, W. K., Kulldorff, M., Fireman, B. H., Shui, I. M., Lewis, E. M., Klein, N. P., ... Lieu, T. A. (2011). Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. *Pediatrics*, 127 Suppl 1, S54-64. <https://doi.org/10.1542/peds.2010-1722l>

References – Chapters 10.3.

- Amstutz, U., Shear, N. H., Rieder, M. J., Hwang, S., Fung, V., Nakamura, H., CPNDS clinical recommendation group. (2014). Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. *Epilepsia*, 55(4), 496–506. <https://doi.org/10.1111/epi.12564>
- Balding, D. J. (2006). A tutorial on statistical methods for population association studies. *Nature Reviews. Genetics*, 7(10), 781–791. <https://doi.org/10.1038/nrg1916>
- Bozkurt, O., Verschuren, W. M. M., van Wieren-de Wijer, B. M. A., Knol, M. J., de Boer, A., Grobbee, D. E., Klungel, O. H. (2008). Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. *Journal of Human Hypertension*, 22(11), 774–780. <https://doi.org/10.1038/jhh.2008.62>
- Carleton, B., Poole, R., Smith, M., Leeder, J., Ghannadan, R., Ross, C., Hayden, M. (2009). Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. *Pharmacoepidemiology and Drug Safety*, 18(8), 713–721. <https://doi.org/10.1002/pds.1772>
- Carr, D. F., O'Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., Pirmohamed, M. (2013). SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. *Clinical Pharmacology and Therapeutics*, 94(6), 695–701. <https://doi.org/10.1038/clpt.2013.161>
- CPIC: Clinical Pharmacogenetics Implementation Consortium. (n.d.). Retrieved April 9, 2018, from <https://cpicpgx.org/>
- Dennis, J., Hawken, S., Krewski, D., Birkett, N., Gheorghe, M., Frei, J., Little, J. (2011). Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. *International Journal of Epidemiology*, 40(5), 1329–1341. <https://doi.org/10.1093/ije/dyr088>
- Drews, J. (2000). Drug discovery: a historical perspective. *Science (New York, N.Y.)*, 287(5460), 1960–1964.
- Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. *Science (New York, N.Y.)*, 286(5439), 487–491.
- Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. *Nature*, 429(6990), 464–468. <https://doi.org/10.1038/nature02626>
- Gatto, N. M., Campbell, U. B., Rundle, A. G., & Ahsan, H. (2004). Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias. *International Journal of Epidemiology*, 33(5), 1014–1024. <https://doi.org/10.1093/ije/dyh306>
- Grady, B. J., & Ritchie, M. D. (2011). Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis. *Current Pharmacogenomics and Personalized Medicine*, 9(1), 41–66. <https://doi.org/10.2174/187569211794728805>
- Guideline for data analysis of genomewide association studies. (n.d.). Retrieved April 9, 2018, from <https://www.ncbi.nlm.nih.gov/pubmed/17726238>
- Jorgensen, A. L., & Williamson, P. R. (2008). Methodological quality of pharmacogenetic studies: issues of concern. *Statistics in Medicine*, 27(30), 6547–6569. <https://doi.org/10.1002/sim.3420>
- Khoury, M. J., & Flanders, W. D. (1996). Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! *American Journal of Epidemiology*, 144(3), 207–213. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8686689>
- Little, J., Higgins, J. P. T., Ioannidis, J. P. A., Moher, D., Gagnon, F., von Elm, E., Birkett, N. (2009). Strengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. *European Journal of Clinical Investigation*, 39(4), 247–266. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19297801>

- Liu, Y., Nyunoya, T., Leng, S., Belinsky, S. A., Tesfaigzi, Y., & Bruse, S. (2013). Softwares and methods for estimating genetic ancestry in human populations. *Human Genomics*, 7, 1. <https://doi.org/10.1186/1479-7364-7-1>
- Madadi, P., Amstutz, U., Rieder, M., Ito, S., Fung, V., Hwang, S., CPNDS Clinical Recommendations Group. (2013). Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. *Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharamcologie Clinique*, 20(3), e369-396. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/24214521>
- Molokhia, M., & McKeigue, P. (2006). EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics*, 7(4), 633–638. <https://doi.org/10.2217/14622416.7.4.633>
- Peters, B. J. M., Rodin, A. S., de Boer, A., & Maitland-van der Zee, A.-H. (2010). Methodological and statistical issues in pharmacogenomics. *The Journal of Pharmacy and Pharmacology*, 62(2), 161–166. <https://doi.org/10.1211/jpp.62.02.0002>
- PharmGKB (The Pharmacogenomics Knowledgebase). (n.d.). Retrieved April 9, 2018, from <https://www.pharmgkb.org/>
- Pritchard, J. K., Stephens, M., Rosenberg, N. A., & Donnelly, P. (2000). Association Mapping in Structured Populations. *American Journal of Human Genetics*, 67(1), 170–181. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287075/>
- Psaty, B. M., Smith, N. L., Heckbert, S. R., Vos, H. L., Lemaitre, R. N., Reiner, A. P., Rosendaal, F. R. (2002). Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. *JAMA*, 287(13), 1680–1689. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11926892>
- Ross, S., Anand, S. S., Joseph, P., & Paré, G. (2012). Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. *JRSM Cardiovascular Disease*, 1(1). <https://doi.org/10.1258/cvd.2012.012001>
- Storey, J. D., & Tibshirani, R. (2003). Statistical significance for genomewide studies. *Proceedings of the National Academy of Sciences of the United States of America*, 100(16), 9440–9445. <https://doi.org/10.1073/pnas.1530509100>
- van der Baan, F. H., Klungel, O. H., Egberts, A. C. G., Leufkens, H. G., Grobbee, D. E., Roes, K. C. B., & Knol, M. J. (2011). Pharmacogenetics in randomized controlled trials: considerations for trial design. *Pharmacogenomics*, 12(10), 1485–1492. <https://doi.org/10.2217/pgs.11.95>
- van der Baan, F. H., Knol, M. J., Klungel, O. H., Egberts, A. C., Grobbee, D. E., & Roes, K. C. B. (2012). Potential of adaptive clinical trial designs in pharmacogenetic research. *Pharmacogenomics*, 13(5), 571–578. <https://doi.org/10.2217/pgs.12.10>
- van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A.-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffrers, P., Klungel, O. H. (2009). Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. *Journal of Hypertension*, 27(1), 61–68. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19145769>